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ABSTRACT
INTRATHECAL AAV9.TRASTUZUMAB FOR TUMOR PROPHYLAXIS AND TREATMENT IN A
MURINE XENOGRAFT MODEL OF HER2+ BREAST CANCER BRAIN METASTASES
William Thomas Rothwell
James M. Wilson

Breast cancer brain metastases (BCBM) are a deadly sequela of breast tumors that overexpress
human epidermal growth factor receptor 2 (HER2). HER2+ BCBM affects approximately 17,000
women in the US every year. Median survival is 10-13 months from the time of diagnosis of
central nervous system (CNS) disease. Current therapeutic interventions are invasive, toxic, and
largely ineffective, leaving a clear, unmet need for targeted HER2+ BCBM treatments.
Trastuzumab(Herceptin®) is a monoclonal antibody used to treat HER2+ breast cancer
successfully, but systemic trastuzumab cannot bypass the blood-brain barrier (BBB). To solve
this problem, we have developed an adeno-associated virus serotype 9 (AAV9) vector to express
trastuzumab in vivo after a single intrathecal (IT) injection. IT vector administration in an
orthotopic Rag1-/- murine xenograft model of HER2+ BCBM led to a significant increase in
median survival and attenuated brain tumor growth. We also report preservation of both the
HER2 antigen specificity and the natural killer (NK) cell-associated mechanism of action of
trastuzumab. Finally, we demonstrate increased median survival when IT AAV9.trastuzumab is
administered as tumor treatment. Our results indicate that IT AAV9.trastuzumab may provide
significant anti-tumor activity in patients with HER2+ BCBM.
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CHAPTER 1
Adeno-associated virus (AAV)
AAV is a small, non-enveloped parvovirus of the dependoviridiae family originally
discovered as a contaminant in laboratory cultures of adenovirus in 1965 [1]. It has a
single-stranded DNA genome which is about 4.7 kilobases in length and contains two
genes, rep and cap. These genes code for full-length non-structural and viral capsid
proteins, respectively, as well as multiple splice variants of each. These genes are
flanked by inverted tandem repeat sequences (ITRs) of 145 base pairs in length, which
serve to prime second strand synthesis of the viral genome in a host cell. They can also
prime transcription of viral genes. AAV is not known to cause any disease in humans
and can infect both dividing and non-dividing cells. [2-6]
Multiple AAV serotypes exist and are defined by differences in amino acid
sequence of capsid proteins. Each serotype has a unique tropism for tissues in the body,
thus allowing the engineering of AAV gene therapy vectors targeted to a particular organ
or set of organs. The serotypes of the first nine AAVs discovered are indicated by a
number (AAV1 or AAV2, for example). As more AAVs were discovered, this convention
has changed to reflect the species of origin (AAVrh10 from rhesus macaques, AAVhu32
from humans, etc.) [7-12].
Wild-type AAV infection begins when a virion binds to a host cell. The full
mechanism of attachment and entry is still incompletely understood. Recently, a panAAV receptor (AAVR) for AAV binding was reported [13]. Previously, Bell et al. showed
that gene therapy vectors derived from AAV serotype 9 (AAV9) require a terminal
galactose residue on host cell glycoproteins for entry [14]. In any case, binding to the
1

host cell leads to endocytosis of virions. Endocytosis of virions is necessary for
successful infection, as direct injection of virions into the cytoplasm does not lead to
virion localization to the nucleus. After trafficking through early endosomes, virions
escape and are translocated to the nucleus where they uncoat. The AAV genome
remains episomal in the nucleus, forming head-to-tail concatamers. [5, 15-23]
Whether or not AAV genomes have the ability to integrate into the host genome
at a specific point on chromosome 19, termed AAVS1, is debated. Regardless, AAV
infection alone is a lysogenic event. In order for wild-type AAV to replicate and complete
a lytic cycle, coinfection with adenovirus and/or expression of required adenovirus
proteins in the host cell is required. [5, 15-23]

AAV gene therapy vectors
To engineer a non-replicating AAV gene therapy vector from wild-type AAV, one
simply replaces the rep and cap genes in the AAV genome with an expression cassette
containing the therapeutic gene of interest (transgene) as well as necessary regulatory
elements including an enhancer/promoter and polyadenylation signal. The ITRs are left
intact, flanking the expression cassette. By convention, gene therapy vectors use ITR
sequences from AAV2. Rather than relying on adenovirus coinfection to provide proteins
required to complete the AAV life cycle, they are provided in trans. [24]
One common method of AAV vector production involves co-transfection of
human embryonic kidney 293 cells (HEK293) with three plasmids. One plasmid is the
vector genome itself containing the transgene expression cassette, another contains the
necessary adenoviral protein genes, and a third contains the capsid protein gene for the
2

desired AAV serotype. Vector genomes are packaged into the AAV capsids that selfassemble intracellularly, and the host HEK293 cells are lysed to collect vector.
Interestingly, HEK293 cells were first developed after transformation of embryonic
kidney cells with sheared adenovirus DNA. Thus, HEK293 cells already possess some
of the adenoviral proteins necessary for AAV vector production. [24]
Self-complementary (scAAV) AAV vectors were developed as a way to speed the
onset of transgene expression. The genomes of these vectors are engineered to skip
second strand synthesis, since a self-complementary genome will form a doublestranded molecule in vivo on its own. [24]
Most humans have been infected with at least one serotype of wild-type AAV,
likely at a young age as antibodies to AAVs have been reported in children. Infection
with either wild-type AAV or systemic administration of an AAV vector leads to a potent
antibody response against the capsid protein. These antibodies may simply bind to the
capsid protein, or the antibodies may neutralize the virus/vector (termed neutralizing
antibodies or nAbs), rendering the particle unable to transduce a host cell. nAbs may be
specific for one AAV serotype, or they may be cross-reactive, neutralizing multiple
serotypes. Prevalence of antibodies against different serotypes of AAV is unique to the
serotype in question. AAV9, for example, has a nAb prevalence in humans of about 1530% and a binding antibody prevalence of about 45%. A person’s geographic location
correlates with the prevalence of anti-AAV antibodies, with higher titers of nAbs
occurring in developing countries. [25-33]
The presence of neutralizing antibodies in a patient or laboratory animal are of
particular concern in the field of gene therapy, as titers of neutralizing antibodies in blood
3

greater than 1:10 have been shown to prevent AAV transduction in vivo after systemic
dosing. This would preclude either administration of gene therapy to an individual
altogether or re-administration of an AAV vector of a given serotype to the same patient.
Many laboratories which study AAV are employing various techniques to engineer AAVs
to escape neutralization. It has been suggested that plasmapheresis may serve as a tool
to temporarily lower the titer of anti-AAV antibodies in an individual before gene therapy
vector administration, although multiple plasmapheresis sessions may be required, as a
single session will lower a patient’s AAV nAb titer by only 2 to 3-fold. [25-33]

Approved and forthcoming gene therapies
Several gene therapy products have been developed which have either been
approved by either the Federal Drug Administration (FDA) or European Medicines
Agency (EMA) or which are in clinical trials and are expected to be approved in the near
future. Several of these are AAV gene therapies, but others use different vectors, such
as lentiviral vectors derived from the human immunodeficiency virus (HIV).
The EMA approved the first gene therapy for commercial use in Europe. Glybera
(apolipogene tiparvovec) is manufactured by uniQure based in the Netherlands. Glybera
is an AAV1 gene therapy engineered to deliver the enzyme lipoprotein lipase (LPL) to
patients harboring a very rare genetic deficiency of active enzyme. LPL helps to break
down fat-laden chylomicrons which fill the blood after meals, and familial LDL deficiency
may lead to chronic, life-threatening attacks of pancreatitis. Although Glybera
administration was stated to have led to decreased number of pancreatitis episodes in
patients with LPL deficiency, its true efficacy was hotly debated. To receive Glybera
4

treatment, patients are required to undergo 60 injections of the product into the
quadriceps muscle. Its price tag proved daunting at the equivalent of 1 million USD per
treatment. As such, uniQure announced in April 2017 that it would not seek renewal of
Glybera marketing authorization by the EMA, allowing it to expire in October 2017. [34]
Another AAV gene therapy developed by Spark Therapeutics, voretigene
niparvovec (Luxturna), has shown great promise in clinical trials. Luxturna is an AAV2
gene therapy to treat an inherited form of blindness call Leber congenital amaurosis
(LCA). LCA can be caused by defects in several genes, one of which is RPE65, a
protein that is expressed in retinal pigment epithelial cells and is required for normal
visual function. Using a sub-retinal injection, AAV2 vector with an RPE65 transgene has
been administered to LCA patients and has shown promise in restoring vision,
particularly in younger individuals. An FDA advisory committee recommended approval
of Luxturna in October 2017, and it is likely that it will receive FDA approval in the fourth
quarter of 2017 or first quarter of 2018, becoming the first gene therapy for a genetic
disease licensed in the US. [35]
The very first gene therapy approved by the FDA is an ex vivo form of gene
therapy called Kymriah (tisagenlecleucel). This treatment was approved in August 2017
and is comprised of genetically modified chimeric antigen receptor (CAR) T cells used to
treat B cell acute lymphoblastic leukemia (ALL), an aggressive disease that kills 90% of
patients in the first five years after diagnosis. 83% of patients treated with Kymriah
experienced complete remissions of their disease in trials.
To understand how Kymriah works, it is necessary to elaborate briefly upon T cell
biology. T cells are lymphocytes which form in the bone marrow and mature in the
5

thymus. They harbor a T cell receptor protein on their cell membranes. T cell receptors
can recognize short peptides called epitopes. Epitopes can be derived from foreign
proteins (for example, proteins from a virus or bacterium), self-proteins, mutant selfproteins, etc. Almost all self- reactive T cells are deleted by a complex process in the
thymus during T cell development, although escapees can lead to autoimmunity.
Each T cell receptor recognizes a different epitope, which must be presented to
the T cell receptor in the context of a major histocompatibility complex (MHC) protein.
MHCs are present on all of our nucleated cells in the form of MHCI. MHCI presents
intracellular self- and non-self-epitopes to the periphery. By the process of cross
presentation, MHCI may present endocytosed antigens on specialized antigen
presenting cells, primarily dendritic cells. MHCII is present on the surface of specialized
antigen presenting cells such as dendritic cells, macrophages, or B cells. MHC II
presents epitopes from endocytosed antigens.
Once a T cell encounters its cognate epitope-MHC complex on another cell, as
well as the necessary costimulatory signals, the T cell is primed and activated to divide
and exert effector functions. These effector functions could include killing target cells that
express the cognate epitope of the T cell receptor. This function is mainly performed by
cytotoxic T lymphocytes, which harbor a CD8 molecule. CD8 is costimulatory to MHCIassociated T cell priming. T cells may also exert effector function by releasing cytokines
and signals crucial for priming other arms of the immune response. This function is
mainly performed by T cells which harbor a CD4 molecule. CD4 is costimulatory to
MHCII-associated T cell priming.
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Rather than a conventional T cell receptor, CAR T cells express a receptor with
an extracellular domain consisting of a small antibody construct. One antibody construct
commonly used for this purpose is the short chain variable fragment (scFv), which is
described further in “Antibodies” in chapter 3. In the case of Kymriah, the CAR scFv is
murine and targets the human B cell protein CD19, which is expressed on all B cells
including B cell leukemias and lymphomas. The advantage of using an antibody
construct in this context is that the CD19 epitope does not have to be presented to the T
cell in the context of an MHC. Rather, it can bind directly to its epitope. Additionally, the
membrane-associated and intracellular domains of CAR T cells are engineered to
provide potent co-stimulatory signaling machinery for the T cell to be induced to kill the
target B cells. Thus, these CAR T cells are designed for fast, efficient, and specific
recognition and killing of target cells.
Kymriah is derived from a patient’s own T cells, which are separated in the clinic
from peripheral blood. Rather than AAV, lentiviral vectors are used to transfer the CAR
gene to the T cells ex vivo, resulting in integration of the CAR expression cassette into
the T cell genome. The cells are expanded and activated in vitro, then infused back into
the patient. CAR T cells have led to ALL remissions in patients with high-stage disease
who have failed other therapies. However, the toxicity associated with the release of
large amounts of cytokines in these patients has resulted in patient mortality. As such,
the FDA approved the use of Kymriah with an extensive risk evaluation and mitigation
strategy over the next 5 years. Additionally, patients’ healthy B cells are also targeted by
CD19 CAR T cells, necessitating regular infusions of intravenous immunoglobulin in
recipients. [36, 37]

7

In summary, the field of gene therapy is growing at an exponential rate. New
therapies for diseases once considered incurable are now contenders for cutting-edge
treatments. The emergence of AAV gene vectors has contributed to this boom, and it is
expected the FDA will soon approve more AAV gene therapies that are currently in
clinical trials or pre-clinical development for use in patients.
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CHAPTER 2

The blood-brain barrier and cerebrospinal fluid
The blood-brain barrier (BBB) is a physiological barrier separates the central
nervous system (CNS) from the blood. It serves to protect the brain from organisms and
toxins that may be present in the circulation. The BBB is formed both by astrocytyes and
endothelial cells that line blood vessels in the CNS. These endothelial cells lack the
usual fenestrations found in vascular endothelium elsewhere in the body; rather, they
are held together by tight and adherens junctions. Astrocytic end feet also wrap around
these blood vessels, forming another barrier. The BBB prevents the movement of large,
polar, or charged molecules as well as cells from entering the CNS indiscriminately.
Transport proteins expressed at the BBB do allow specific transfer of macromolecules
from blood to CNS, and certain immune cells can access the CNS by moving
intracellularly through the BBB. [38-40]
Cerebrospinal fluid (CSF) is the liquid that bathes the brain and spinal cord,
serving both as a cushion to the brain as well as a source of nutrients and waste
clearance for cells of the CNS. It is made from plasma that is transported by pinocytosis
into the CNS by specialized anatomical structures such as the choroid plexus and
ependymal cells, which are discussed below. CSF is much like plasma in composition
except that most proteins and cells are excluded in its production. [38-40]
Traditionally, 80% of CSF is said to be secreted by a net-like structure called the
choroid plexus, which floats in the lateral ventricles of the brain and is formed of a layer
of cuboidal epithelial cells held together by tight junctions which line the outside of
9

capillaries. Other sources of CSF include ependymal cells, ciliated columnar epithelial
cells which line both the lateral ventricles and central canal of the spinal cord, and the
brain parenchyma itself. [38-40]
CSF flows around CNS structures and eventually joins back with venous blood at
the one-way valve-like arachnoid granulations, also called arachnoid villi, located in the
venous sinuses of the skull. A small portion of CSF is thought to return to venous
circulation along the perineural spaces surrounding cranial nerves. CSF pulsates around
CNS structures, moving with an individual’s respiration. These pulsations are thought to
originate at the choroid plexus and also by way of the ependymal cilia. In humans, the
rate of CSF formation is 0.2-0.7 mL per minute, or 600-700 mL per day, and the total
CSF volume is between 140 – 270 mL, depending on the age and sex of the individual.
Thus, the CSF turns over rapidly. [38-40]

AAV serotype 9 (AAV9)
In the early 2000s, Gao et al. reported discovery of a number of new AAV
serotypes in humans and non-human primates (NHPs) and characterization of their
transduction patterns. A new AAV serotype, AAV9, emerged as a promising candidate
for gene therapy in the central nervous system (CNS) due to its superior transduction of
neurons and glial cells in vivo. AAV9 can also transduce liver, heart, and skeletal
muscle. [10]
Cearley and Wolfe reported the widespread pattern of AAV9 CNS transduction in
rodents after intravenous (IV) administration of vector, suggesting that AAV9 may cross
the blood-brain barrier (BBB). Further studies in NHPs indicated that although IV10

administered AAV9 vectors may cross the blood-brain barrier to a small extent by way of
an unknown mechanism, the amount of transduction in the brain itself after IV
administration of vector is not enough to guarantee successful therapeutic efficacy of a
gene therapy unless exceptionally large doses are used. As such, a more targeted route
of administration (ROA) for AAV9 delivery to the CNS was in order. [41-48]

Intrathecal administration of AAV9 gene therapy vectors
Several groups have demonstrated that bypassing the BBB with an intrathecal
(IT) injection of AAV9 directly into central nervous system (CNS) leads to superior
transduction of cortical and cerebellar brain structures compared to IV AAV9 vector
administration. Additionally, IT administration of AAV9 will not expose vector to
neutralizing antibodies (nAbs) circulating in the blood. Thus, individuals with high titers of
nAbs may still be eligible to receive IT AAV gene therapy.
There are multiple ways to access the CNS for IT vector administration. One may
inject vector directly into the brain tissue itself (intraparenchymal injection). This
technique involves making multiple needle tracks in the brain parenchyma and releasing
several boluses of vector as the needle is drawn back up the needle track. This may be
the route of administration (ROA) of choice if one desires high levels of local
transduction of small structures in the brain such as the basal ganglia. However, this
technique would not be suitable if one desires widespread AAV transduction in the CNS
as these intraparenchymal injections lead to poor penetration of vector into the brain
parenchyma. In fact, the majority of transduced cells are located in the area immediately
surrounding the needle tracks. To guarantee widespread transduction throughout the
11

cortex by intraparenchymal injection, as is accomplished by roughly 4 intraparenchymal
injections in mice, over 100 individual needle tracks would likely need to be made in the
human brain. Additionally, disruption of brain tissue during intraparenchymal vector
administration can lead to the initiation of an inflammatory response in the brain. This, in
turn, can prime potent immune responses against the vector capsid and transgene
which can damage CNS tissue. [49-51]
One may also inject vector directly into the cerebrospinal fluid (CSF), the fluid
that bathes the brain and spinal cord and is contiguous with brain interstitial fluid. Vector
thus percolates with the CSF around CNS cells leading to widespread transduction of
structures throughout the brain. There are multiple ways by which one may access the
CSF. A lumbar puncture (LP) would involve administering vector directly into the CSF
surrounding the lumbar spinal cord. Intracranioventricular (ICV) administration would
likely involve neurosurgical placement of an Ommaya reservoir, a plastic, dome-shaped
reservoir attached to a catheter. The catheter penetrates the skull and brain
parenchyma, and the tip of the catheter rests in one of the lateral ventricles. CSF flows
out of the ventricles through the catheter and into the bulb portion of the reservoir, which
sits subcutaneously outside of the skull. After placement, one simply pierces the skin
and reservoir with a needle to access CSF. Finally, one may deliver vector by way of
direct injection into the cisterna magna (intra-cisterna magna, ICM), an anatomical
reservoir of CSF located directly below the occipital portion of the skull. [49, 52-55]
AAV9 transduction in the murine CNS has been described in many publications.
Cearley and Wolfe administered AAV9 by direct stereotaxic intraparenchymal injection of
vector into the brains of mice that lacked a lysosomal enzyme required to break down
long carbohydrate molecules called glycosaminoglycans. Patients with family of genetic
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diseases called mucopolysaccharidoses can lack one of a family of these lysosomal
enzymes, leading to toxic accumulation of glycosaminoglycans in the CNS and other
organs of the body.
After intraparenchymal administration of AAV9 vector, transduction of cortical
neurons was evident in cerebral hemisphere ipsilateral to the injections, as expected.
Interestingly, cortical structures in the hemisphere contralateral to the side of vector
administration were also transduced. It was postulated that AAV9 was taken up by
neurons around the injection site and trafficked by way of axons which cross the cerebral
hemispheres, leading to enzyme expression in the contralateral hemisphere. The
hippocampal commissure, septal nuclei, and entorhinal commissure were identified as
candidate structures for this phenomenon, as they contain neurons that send axons to
the contralateral hemisphere. Trafficking of AAV9 along axons was subsequently
confirmed in later papers from the same group. [15, 56]
Schuster et al. described transduction of AAV9 after ICV administration of
AAV9.GFP in mice. GFP expression was widespread throughout the CNS including in
cortical neurons and astrocytes. Specific structures observed to be transduced included
“cranial nerve nuclei, ventral pons, cerebellar cortex, hippocampus, pituitary, choroid
plexus, and selected nuclei of midbrain, thalamus and hypothalamus.” Interestingly,
transduction of the enteric nervous system was also observed. [57]
Many labs have compared administration of AAV9 vector by way of LP or by ICM
injection in large animals, particularly in NHPs. Two reports by Samaranch et al.
describe ICM administration of 1.8e13 genome copies (GC) of scAAV9 vector to a total
of 4 cynomolgus macaques. The transgene expression cassette of the vector was
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comprised of a cytomegalovirus immediate/early enhancer-promoter (CMV) and a green
fluorescent protein (GFP) transgene (scAAV9.CMV.GFP). 3 weeks after vector
administration, animals were euthanized and GFP was detected in CNS tissues both by
immunohistochemistry (IHC) and immunofluorescence (IF) microscopy.
In all animals, GFP was expressed in cells from the prefrontal to occipital cortex
and at all levels of spinal cord. Types of cells transduced included neurons, astrocytes,
and ependymal cells. In the earlier of the two reports, Purkinje cells in the cerebellum
were found to have the strongest GFP expression. GFP expression was also shown to
cluster in cells surrounding blood vessels. In the earlier report, colocalization of GFP
expression with cell type-specific markers showed that GABAergic interneurons were
transduced. In the later report, the authors describe sparse transduction of cells in
spleen and liver, suggesting that vector does indeed escape from the CNS after IT
administration, likely with CSF as it empties into the venous circulation at the arachnoid
granulations. [44, 58]
Grey et al. described administration of scAAV9 vector with a different promoterenhancer, derived from chicken beta-actin (CBh), to express GFP in ten cynomolgus
macaques. Two of these animals received scAAV9.CBh.GFP vector by ICM
administration, and eight received vector by LP. Most animals received 1.83e12 GC
vector, although two animals that received LP vector were dosed at 5.5e12 GC vector.
After four weeks, animals were euthanized, and GFP expression was detected in cells
throughout the cortex by IHC only.
LP vector administration led to greatest GFP expression in lumbar segments of
spinal cord. Using quantitative PCR (qPCR) to determine number of GC in specific
14

anatomical structures, the authors indicated that ICM vector administration led to spinal
cord transduction at a level of 0.08 GC per diploid genome (DG) while LP vector
administration yielded only 0.02 GC/DG. This suggests that ICM administration of vector
is a superior ROA to LP, even for spinal cord gene transfer. Interestingly, qPCR of CSF
collected two hours after vector administration detected no vector, suggesting that the
rapid turnover of CSF also leads to rapid vector clearance. [41]
A pivotal report by Hinderer et al. compares ICM and LP dosing of 6 cynomolgus
macaques with AAV9.GFP. Four animals received vector ICM, two at a dose of 2.5e12
GC/kg and two at a dose of 5e12 GC/kg. The two animals that received vector by LP
were dosed at 2.5e12 GC/kg. One animal also received vector IV at 2e13 GC/kg. This IV
dose was 8-fold higher per kg body weight than the dose given to monkeys by LP and
the lower dose administered to monkeys ICM.
After 14 days, expression of GFP throughout the cortex and spinal cord was
visualized by IF, and GFP-positive neurons were quantified in an automated fashion by
software. Importantly, animals that received vector by ICM dosing showed 10- to 100fold higher levels of gene transfer in the cortical CNS than animals that received vector
by LP. In fact, ICM vector administration in these animals led to better gene transfer in
all divisions of the spinal cord than LP vector administration. Additionally, IV vector
delivery led to similar levels of gene transfer throughout the CNS when compared to LP
vector administration, although the IV dose was much higher. IF colocalization of celltype specific markers demonstrated that AAV9 vector transduced neurons and glia,
including astrocytes. Although the number of lymphocytes in CSF increased after vector
administration, no clinically appreciable or histological toxicity was noted in the animals
during the course of the experiments. [49]
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NHPs are not the only large animals used to study IT administration of AAV9
vector, as porcine models are becoming increasingly prevalent. One report by Federici
et al. describes LP delivery of scAAV9.CBh.GFP to twelve pigs at one of two doses,
4.28e10 GC/kg or 1.7e11 GC/kg. Vector was administered after single level lumbar
laminectomy and catheter placement either “locally,” as a 1.5 mL bolus at the lumbar
level, or “diffusely,” as three 0.5 mL boluses at the cervical, thoracic, and lumbar levels
10 cm apart.
After four weeks, “local” administration led to greater GFP expression at lumbar
levels of the spinal cord, greater GFP expression in spinal cord at the higher dose, and
GFP expression in dura up to the level of the cervical spinal cord. “Diffuse”
administration led to transduction of all segments of spinal cord, but with very little
transduction at the low dose. qPCR analysis of DNA from various tissues showed only
small amounts of transduction of peripheral tissues. Only IHC was used to visualize GFP
expression, with microscopic quantification of transduced neurons performed manually.
[59]
Overall, these studies suggest that unless one desires to target spinal cord
locally, ICM AAV9 vector administration leads to the most extensive transduction of
cortical and cerebellar structures compared LP vector administration. As such, ICM is
the most promising IT ROA for gene therapies that require widespread transduction of
the CNS and expression of either intracellular or secreted transgenes by neurons and
glia throughout the cortex and cerebellum.
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When intra-cisterna magna vector administration is infeasible: The Ommaya
reservoir versus lumbar puncture for access to cerebrospinal fluid

Although ICM vector administration will likely be the preferred method of AAV9
vector delivery for CNS gene therapies going forward, there may be instances where this
ROA is not feasible. In these cases, an LP or Ommaya reservoir may be preferred
methods of access to CSF. The following is an in-depth comparison of both techniques
in terms of safety and feasibility as ROAs for gene therapy vectors targeting the CNS.
The Ommaya reservoir was developed in 1963 by Dr. Ayub Ommaya as a way to
provide easy, subcutaneous access to patients’ CSF to administer drugs for fungal
meningitis [53]. Since then, it has become the method of choice to administer
chemotherapeutic agents directly into the CSF of patients with CNS malignancies.
As described above, the reservoir consists of a plastic, dome-shaped structure
connected to a catheter. To insert it, neurosurgeons shave and incise skin overlying the
non-dominant hemisphere of the brain to expose the skull. Next, a burr hole is drilled in
the skull that is large enough to accommodate the catheter. After penetrating the dura,
the catheter is inserted into the brain parenchyma and advanced to the ventricle. Correct
trajectory of the catheter may be assisted by ultrasound guidance, a stereotactic frame,
or a device such as a Ghajar Guide (Neurodynamics, Inc.) to ensure that the catheter
travels perpendicularly relative to the plane of the patient’s skull. To confirm entry into
the ventricle, the surgeon will test for CSF flow through the catheter. Further
intraoperative fluoroscopic or endoscopic imaging can be used to determine the precise
location of the catheter tip.

17

After confirming proper placement of the catheter, the reservoir is connected,
secured to the skull with suture, and the overlying skin is closed. A computed
tomography (CT) scan may be performed postoperatively to confirm correct placement
of the catheter [54]. To access the reservoir, the overlaying skin is disinfected, and a
needle and syringe is used to puncture the reservoir and withdraw CSF. According to
one study, reservoirs have remained in place anywhere from 2 days to 4.6 years, with a
median of 4.1 months [60]. Both pediatric and adult patients may have an Ommaya
reservoir implanted.
Major complications resulting from placement and access of the Ommaya
reservoir include infection, hemorrhage, and catheter misplacement. One study reported
that 10% of patients with an Ommaya reservoir experienced some sort of complication
[54].
Infections comprise a large portion of these Ommaya reservoir complications.
Two recent retrospective case analyses surveyed reservoir infections at two separate
institutions over a 10 and 16-year period, respectively. 5.5 [61] and 8% [62] of patients
with Ommaya reservoirs developed a device-related infection, which falls within the
previously reported 2-15% infection rate [63-66]. Meningitis or meningoencephalitis
represented the majority of infections.
Most infections occurred soon after the device was accessed (within 7 days [62]
or 30 days [61]). The studies also reported that 32 [61] and 40% [62] of reservoir
infections occurred within the first month after placement. The median number of
reservoir punctures before infection reported in the respective studies was 3 [62] and
5[61], although the range was broad for both studies (0-105 [61]; 2-17 [62]).
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The most commonly isolated bacteria from CSF cultures of patients with infected
reservoirs are normal skin flora, particularly coagulase negative staphylococci (e.g.
Staphylococcus epidermidis) and Proprionibacterium acnes. However, Staphylococcus
aureus, Pseudomonas spp., enteric bacteria, mouth flora, and even Candida spp. have
been cultured as infectious agents [61, 62]. Reported treatments for reservoir infection
range from device removal to intravenous and/or intrathecal antibiotics [62, 67]. Patients
have died as a result of reservoir infections [61, 62].
It is important to note that the majority of patients that receive Ommaya
reservoirs do not contract an infection. One Canadian study reports that 85% of patients
with Ommaya reservoirs had no infection within the first year post-implantation [60]. In
addition, it is important to consider that many patients that receive Ommaya reservoirs
are cancer patients who are likely immunosuppressed and therefore more susceptible to
infection in general.
Hemorrhage is a second complication resulting from reservoir placement,
occurring in anywhere from 1-2.8% of patients [54, 60, 63]. Subarachnoid, subdural, and
intraventricular hematomas may occur. One retrospective study indicates that two of
three reported reservoir-related hemorrhages were fatal. However, these deaths were
associated with anticoagulation or development of thrombocytopenia unrelated to device
placement [54].
Misplacement of the reservoir catheter tip is another significant complication of
Ommaya reservoir implantation, occurring in 2.7-12.5% of patients [54, 68, 69]. Although
various imaging modalities can be used both intraoperatively and postoperatively to
confirm catheter tip placement, there are multiple reports of the catheter tip piercing the
19

brain parenchyma postoperatively [70]. One study reports the death of a patient due to
catheter advancement through the wall of the lateral ventricle, thalamus, and into the
midbrain [60].
Despite these morbidities, the Ommaya reservoir offers several advantages to
patients who would receive intrathecal gene therapy. Only one procedure is needed to
provide CSF access for both vector administration and subsequent sampling. CSF
access requires a simple subcutaneous needle stick. Finally, the Ommaya reservoir is
reported to be more comfortable for patients than serial LPs [71].
Alternatively, clinicians may use LP as a method to access the CSF for gene
therapy. LP was first reported by Heinrich Quincke in 1891 as a method to drain CSF
from pediatric patients who had increased intracranial pressure due to tuberculous
meningitis [72]. Today, it is a commonly used technique in both adults and children to
diagnose CNS infections and to identify suspected subarachnoid hemorrhages when CT
scans are negative [55].
To perform a LP, the patient may sit or lie on his or her side in a fetal position
with the back and head bent forward. The clinician palpates the vertebrae of the spine to
locate the 3rd, 4th, and/or 5th lumbar vertebrae (L3, L4, and L5), which are located below
the termination of the spinal cord. The skin above this area is disinfected and draped,
and local anesthesia to the skin is administered. A spinal needle is advanced between
L3 and L4 or L4 and 5 until the CSF from the subarachnoid space begins to flow through
the needle. Often a “pop” is felt as the needle penetrates the dura. The clinician can then
instill medication or anesthesia or withdraw CSF for analysis. Up to 40 mL of CSF may
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be taken from a patient, although a 8-15 mL volume is more commonly collected for
analytic purposes [73].
LPs are usually conducted freehand, although fluoroscopic or ultrasound
guidance can increase the success of the procedure [74-76]. In children, LPs are
performed using the same procedure as in adults with one exception. At birth, the
termination of the spinal cord is located at L3, thus a patient younger than 1 year should
receive a LP below the L2 and L3 vertebrae to avoid piercing the spinal cord [77].
Minor complications associated with LP include post-LP spinal headache, back
pain, radicular pain and limb numbness, and abducens nerve palsy. These sequelae
occur with much greater frequency than the major complications that include
hemorrhage, cerebral herniation, and epidermoid tumors [78].
The most common sequela of LP is the post-LP spinal headache. The onset of
the headache is usually within 5 days of the procedure [79] and occurs commonly in the
front-temporal or occipital regions [80]. It is exacerbated by sitting upright or standing,
and it is ameliorated by reclining [80]. The reported incidence of spinal headache postLP is variable depending on the case series. One study examined several case reports
and reported spinal headache incidence anywhere from 12-40%. This large range is due
to several factors including the gauge of needle used to perform the LP as well as
technique of the clinician [79]. In adults, it has been shown that using a needle with a
smaller diameter lessens the incidence of spinal headaches, as does using a pencilpoint spinal needle rather than one with a beveled end [81-85]. These alterations do not
lessen the incidence of spinal headache in children [86].

21

There are several proposed pathophysiological mechanisms to explain the
etiology of the spinal headache including persistent CSF leakage from the LP access
point, decreased CSF pressure causing tension on the pain-sensitive lining of the brain
and CNS blood vessels, and increased vasodilatation in the brain [87, 88]. Regardless,
the headache is usually self-limiting, with 70% of patients recovering within a week [89,
90]. Caffeine can be taken to relieve pain and possibly decrease the duration of the
headache [91, 92]. In cases where the headache is especially severe or abates slowly,
an epidural blood patch or surgical closure of the hole in the dura can be employed to
stop the headache [83, 93, 94].
Blood in the CSF is a relatively common occurrence in CSF collection and is
referred to as a “traumatic” or “bloody tap.” This occurs if the spinal needle pierces an
epidural vein [78]. Rarely, however, severe hemorrhage due to severing of subdural and
subarachnoid vessels can lead to subarachnoid, epidural, or subdural hematomas that
may compresses the spinal cord causing neurologic deficits and possibly death [95]. As
is the case for patients that receive Ommaya reservoirs, patients that are anticoagulated
after the LP procedure or who have a bleeding diathesis are at higher risk for hematoma
post-LP [95]. If a hematoma does form in the spinal canal, it may require surgical
decompression. Additionally, the patient may experience permanent sensory or motor
damage [96].
Other complications of LP include back pain and paresthesia in the lower
extremities and groin [73]; these are relatively common during and immediately after the
procedure. Cerebral herniation through the foramen magnum due to increased
intracranial pressure (ICP) is a fatal complication of LP. A CT scan should thus be
conducted for all patients exhibiting signs of increased ICP before LP is performed [73].
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Meningitis is rarely experienced following an LP obtained for diagnostic purposes [97]
and is usually associated with poor disinfection of skin or instruments used for the
procedure, poor aseptic technique, or (somewhat controversially) contamination by
mouth flora of the clinician or hospital staff performing or assisting with the LP [98].
Epidermoid tumors are another uncommon sequela of LP and are thought to result from
seeding of the subarachnoid space with epidermoid tissue dislodged during the
procedure. Most of these epidermoid tumors are discovered in early to late childhood in
patients who received LPs as infants [78, 99, 100].
LPs are advantageous for gene therapy applications because they do not require
a specialist to perform. Most internal medicine or pediatric clinicians are trained to
perform an LP. LPs are much less invasive, quicker, and cheaper than implanting an
Ommaya reservor. In addition, the incidence of severe complications or infections for
LPs is universally recognized to be very low.
In order to choose the best route of administration and subsequent access to
CSF for gene therapies in the CNS, one may consider how treatment may progress for a
patient who undergoes Ommaya reservoir implantation versus one who receives serial
LPs.
In one case, the patient would undergo surgery to implant the Ommaya reservoir
prior to vector administration. In the absence of subsequent infection, it is feasible to
assume that vector may be instilled through the reservoir soon after recovery from the
implantation procedure. CSF would be collected from the reservoir, perhaps at 7, 14, 30,
60, and 90 days after vector administration to evaluate transgene expression and
immune responses.
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A high index of suspicion for infection would be maintained through the course of
treatment and evaluation given the increased likelihood of infection within 7 to 30 days of
last reservoir access. The number of reservoir taps may be increased, although this
would exceed the 3 and 5 taps reported above as the median number of reservoir
accesses before infection occurs. The risk of infection may be mitigated if the patient is
not immunocompromised due to cancer or chemotherapy treatment. Patients with a
bleeding diathesis due to thrombocytopenia or clotting factor deficiencies would require
close monitoring and a low threshold for CT imaging to catch hemorrhages early. Adult
patients or families of pediatric patients who experience great distress at the prospect of
serial LPs or who find LPs unbearably painful or uncomfortable may decide that the
convenience of an Ommaya reservoir outweighs its risk of morbidity and mortality.
In the second case, the patient would receive a gene therapy vector intrathecally
by any number of methods including but not limited to instillation through an Ommaya
reservoir that is removed within days of treatment. The patient would then experience
serial LPs punctures to collect CSF for transgene and immunological analysis, again
perhaps at 7, 14, 30, 60, and 90 days post-treatment. The risk of infection due to LP for
this patient would be low, thus clinical suspicion in response to CNS abnormalities would
be focused on complications caused by gene therapy. The same precautions for patients
prone to hemorrhage would be taken in this instance as described above. It is likely that
at least one of these LPs would result in a spinal headache and back pain, both of which
would likely dissipate within several days to a week. It is possible that the patient will
experience radiculopathy and paresthesia during or after the procedure, and it would be
very unlikely for the patient will develop an epidermoid tumor, abducens palsy, or
cerebral herniation (unless, in the latter case, the gene therapy treatment leads to
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increased ICP that is not detected before LP is performed). Overall, serial LPs would be
relatively safe following gene therapy treatment.
Ultimately, the factors that will determine whether the Ommaya reservoir or serial
LPs are chosen for an individual patient or specific treatment may be further dictated by
the expertise of the clinician and center at which therapy is initiated, the patient’s
immune competency, the patient’s propensity to bleed, whether spinal cord cells are the
targets of gene transfer for a given therapy, and the level of comfort the patient or his or
her family has for either modality.
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CHAPTER 3
Antibodies
Antibodies are proteins produced by the immune system in response to the
introduction of proteins that the body senses as foreign. These foreign proteins could
come from a virus, bacterium, or a transplanted organ. Each individual antibody attaches
to a very specific region of this foreign protein. This region of binding is called an
epitope. The epitope may be linear, composed of an adjacent sequence of 5 to 20 amino
acids, or the epitope may be conformational, meaning that it is comprised of nonadjacent amino acids that exist near each other in the three-dimensional confirmation of
the protein. The protein containing these epitopes is called an antigenic protein or
antigen. This antigen may also be another macromolecule, for example a carbohydrate
or glycoprotein.
Antibodies are produced by a specialized immune cell called a B cell, a
lymphocyte of the immune system which develops and matures in the bone marrow.
Each B cell produces an antibody that has unique specificity for a particular epitope.
Upon exposure to its specific antigen along with costimulatory signals from other
immune cells, B cells begin to secrete antibodies. At first, the antibodies tend to have a
relatively low affinity for a particular antigen, meaning the strength of the attachment is
relatively low. As time goes by, the B cells undergo a process called affinity maturation
whereby the strength of attachment of these secreted antibodies increases due to
random mutations specifically in the antibody gene.
Activated B cells will divide to produce a clone of cells. Some members of this
clone will become plasma cells, which are long-lived cells and specialized to produce a
26

large amount of antibody. As the immune response progresses and diminishes, some B
cells become memory cells, specialized to re-activate upon secondary exposure to
antigen and secrete antibodies again.
Antibodies are also called immunoglobulins (Ig). There are several types of Igs
including IgG, IgM, IgA, IgE, and IgD, each of which have structural similarity and serve
a specific purpose in an immune response. IgM, for example, is a large, bulky molecule
of approximately 970 kDa that is the first type of antibody secreted by a B cell when it
encounters its antigen. IgA is shaped like two Ys connected at their stalks and is
produced at mucosal surfaces. IgE is a Y-shaped molecule secreted in response to
allergens. IgG is described in the next paragraph.
After a B cell encounters its antigen and secretes IgM, the B cell undergoes a
process called class switching and begins to secrete IgG, a 150 kDa Y-shaped Ig made
of four polypeptide chains, two heavy and two light chains. The stalk of the Y is called
the crystallizable fragment (Fc), and the two shorter “prongs” are each called antigenbinding fragments (Fab). An IgG has two sites for antigen attachment, one at each end
of the two Fabs. The sites of antigen attachment are comprised of complementarity
determining regions (CDRs) and confer the antigen/epitope specificity of a given
antibody. This specificity is unique to the antibodies produced by a single B cell or clone
of B cells.
The structure of an antibody can also be described with respect to protein
domains or regions. An IgG is made of four types of domains, three constant domains
comprised of the Fc plus the lower portion of the Fab and one variable domain at the
end of the Fab prongs. The variable domain encompasses the CDRs. Constant domains
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on the heavy chain of an IgG are numbered (CH1, CH2, CH3), with CH3 existing at the
bottom of the stalk of the IgG. The light chain constant regions are termed CL. Variable
regions on the heavy and light chains are called VH and VL, respectively, and the
combined heavy and light chain variable regions are termed Fv.
When an antigen is delivered to an individual, many B cells may be stimulated to
produce antibodies against different parts of the antigenic protein. If one were to harvest
these B cells, each antibody produced by different clones of B cells would have a unique
set of CDRs, and each antibody may play one of many different functions in the
clearance of the antigen from the body. Some antibodies may opsonize the foreign
protein, binding to it and signaling to phagocytic cells to engulf the protein or organism
on which the protein is found. This is called opsonization. At other times antibodies serve
as flags to other immune cells such as natural killer (NK) cells to kill the cell harboring
the antigen. Antibodies may also activate the complement cascade.
The antibodies produced by a single B cell or a genetically identical clone of B
cells are called monoclonal antibodies. These antibodies have the same amino acid
sequence and CDRs, and they attach to the same epitope on a given protein. In
contrast, polyclonal antibodies are antibodies all targeted against the same antigen, but
they are produced by multiple B cells or B cell clones. The epitopes of polyclonal
antibodies are located on many different places on the same antigenic protein.
IgGs can be further divided into sub-classes which differ from each other slightly
in the sequence of the Fc and their functions in the body. In humans, the four IgG
subclasses are IgG1, IgG2, IgG3, and IgG4. Each sub-class differs in its affinity for Fc
receptors on effector cells, complement cascade factor C1, the neonatal Fc receptor
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(described below), etc. Fc-binding receptors are generally called Fc receptors (FcRs),
with FcγRs being FcRs that bind to IgG as opposed to IgA (FcαRs) or IgE (FcεRs).
Different IgG subclasses mediate different IgG effector functions. IgG1, for
example, has a high affinity for activating FcγRs, while IgG4 has a much lower affinity for
these receptors. As such, immune cells such as NK cells that express activating FcγRs
will bind to the Fc region of IgG1 and be stimulated to exert their effector functions. IgG4,
however, has low affinity for activating FcγRs, so NK cell effector function is not induced
by IgG4.
To make a monoclonal antibody in the laboratory, B cells are harvested from an
individual or animal and are fused with a myeloma tumor cell to immortalize it. The
resulting “hybridoma” cells are individually sorted into cell culture plates. They divide
continuously forming a clone which secretes a unique monoclonal antibody into cell
culture supernatant. The antibody can be purified from this supernatant and
characterized in terms of its epitope and function.
Scientists and physicians have used monoclonal antibodies for decades in
applications from the laboratory to the clinic. The first report of production of monoclonal
antibodies by the hybridoma method described above was in 1975 [101]. From 1980 to
1982, monoclonal antibodies against human lymphoma-associated antigen were first
administered to human patients to treat T cell lymphoma as well as gastrointestinal
tumors. The Nobel Prize in Medicine was awarded in 1984 to Niels K. Jerne, Georges
J.F. Köhler and César Milstein for “the specificity in development and control of the
immune system" and the discovery of "the [hybridoma] principle for production of
monoclonal antibodies.” In 1997, the FDA approved the first therapeutic monoclonal
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antibody to treat B cell non-Hodgkin lymphomas, rituximab (Rituxan). Although the US
patent for rituximab expired in 2015, it is still used today in the clinic. [102-105]
Proteins that are introduced from one species of animal into another are often
immunogenic in the recipient animal and lead to production of antibodies against the
foreign protein. Introduction of a mouse protein into a goat, for example, will likely cause
the goat to develop an IgM and then IgG response to the mouse protein. This antispecies antibody production can be utilized by scientists to raise antibodies against
human proteins for therapeutic use.
Of note, amino acid sequences of antibodies also differ among species. This
means that introduction of a mouse IgG into a goat could cause the goat to develop antimouse IgG antibodies. Therefore, if scientists isolate an IgG with therapeutic potential
from a mouse, it is possible that patients that receive that same IgG will develop an
immune response against it, rendering it ineffective.
To prevent this from happening, recombinant DNA techniques can be used to
produce chimeric antibodies. Chimeric antibodies are made by grafting the Fv portion of
the desired, non-human IgG onto the constant regions of a human IgG. Rituximab,
described above, is a chimeric IgG specific for human CD20 protein on B cells that was
originally raised in a mouse injected with human CD20 protein [106-108]. During the
development of rituximab, the murine constant regions of the most therapeutically
promising mouse anti-human CD20 monoclonal antibody was replaced with human
constant regions, making rituximab less immunogenic to patients.
So called humanized antibodies replace the non-human IgG constant regions
and almost all of the Fv with human IgG sequence. The non-human CDRs, which
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include several “framework” amino acids that play a necessary role in CDR-epitope
binding, are left intact. The result is an even less immunogenic IgG. Fully human
antibody sequences can either be directly isolated from humans or from mice genetically
engineered to express human antibodies.
Genetic engineering can also be used to make antibody constructs, non-naturally
occurring antibody-like proteins that maintain the antigen specificity of an antibody with
or without the associated Fc-mediated effector function. One example of an antibody
construct is an immunoadhesin. Immunoadhesins are proteins that are translated in a
single reading frame as opposed to multiple reading frames as is the case for a fulllength antibody. The immunoadhesin heavy and light chain sequences are connected by
a linker peptide that allows the expressed protein to form the Y-shaped structure of an
IgG. Immunoadhesins lack CH1, located on the lower portion of the prongs of the IgG,
making the DNA sequence of an immunoadhesin shorter than that of a full-length IgG.
Because the immunoadhesin maintains a normal stalk portion of the IgG Y-shape, it can
still mediate FcR functions and has a half-life similar to full-length antibodies.
Another antibody construct is the scFv. Here, the VH and VL of an antibody are
also translated in a single reading frame, connected by a linker peptide of 10-25 amino
acids. In vivo, these proteins form into an Fv-like structure which can bind to an epitope.
scFvs do not have an Fc, therefore they cannot mediate Fc effector functions. Their halflife in blood is also much shorter than that of full-length IgG.
In fact, IgG has an unusually long half-life in blood, 10 to 18 days, compared to
other Igs. IgA or IgM have a half-life of only 5 to 6 days. This longer IgG half-life is due to
the recycling function of the neonatal Fc receptor (FcRn). FcRn was originally
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discovered in placenta where it transports antibodies from the blood of a mother to her
fetus. It is expressed on many other tissues in the body where it plays various roles.
In the circulatory system, FcRn is expressed on the apical surface of endothelial
cells lining blood vessels. These endothelial cells constitutively pinocytose plasma,
which contains IgG as well as other Igs and proteins. The endosomes resulting from this
pinocytosis are acidified and traffic to lysosomes where protein contents are normally
degraded. However, IgG escapes this fate. As endosomes are acidified, IgG binds to
FcRn in the lumen of the endosome. The FcRn-IgG complexes are then sorted into
recycling endosomes which transport the IgG back to the apical plasma membrane.
After the recycling endosome fuses with the plasma membrane, IgG dissociates from
FcRn at physiological pH. This recycling function of FcRn is what gives IgG a long halflife in the blood. [109]
Section References
Male, D.K., Immunology. 8th ed. 2013, Elsevier/Saunders: United States, 472 pp.[110]
Murphy, K.P., et al., Janeway's Immunobiology. 8th ed. 2012, New York: Garland
Science. 868 pp. [111]

AAV-mediated delivery of antibodies
IgG antibodies are proteins coded by genes. The human IgG heavy and light
chain DNA sequences are approximately 1345 base pairs (bp) and 645b bp long,
respectively. An antibody gene sequence can easily fit into an AAV genome along with
the requisite regulatory elements. Thus, AAV vectors can be used to deliver the gene for
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a monoclonal antibody to patients so that the patients’ own cells will produce the
therapeutic antibody in vivo. [112]
Expression cassettes designed for whole antibody gene transfer by AAV vectors
must be engineered to express both the heavy and the light chains of an antibody. This
can be accomplished from the same expression cassette in several ways. One method
is to place an internal ribosome entry site (IRES) between the heavy and light chain
sequences in the expression construct. However, for successful expression of a whole
antibody, it is necessary for the light and heavy chain proteins to be produced at a 1:1
ratio. Greater expression of light chain over heavy chain, for example, can lead to
intracellular toxicity as well as pathologic deposition of complexes formed by aggregation
of light chain in various organs. As the sequence upstream of the IRES in the expression
construct may be translated more efficiently, using an IRES may cause unequal
production of heavy and light chains. [113]
Instead, using a so-called 2A peptide motif between the light and heavy chain
sequences allows for translation of the heavy and light chains together followed by a
“self-cleavage” event during translation. 2A motifs are derived from viruses. For
example, F2A was derived from foot-in-mouth virus. Self-cleavage of the 2A polypeptide
occurs between a glycine and proline residue at the C terminus. The addition of a furin
recognition sequence upstream of the 2A but downstream of the first gene allows
removal of the 2A residues from the upstream gene by furin enzymatic cleavage. Using
this technique, equal ratios of heavy and light chains are produced, increasing the
efficiency and safety of antibody gene translation over the use of an IRES. [113]
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An alternative to expressing a whole antibody is expressing an antibody
construct, many of which are transcribed in a single reading frame and form the correct
conformation in vivo. These antibody constructs may include the immunoadhesin or
scFv, described above.
Using AAV vectors to deliver monoclonal antibodies to patients is not a novel
concept. Balazs et al. and Johnson et al. pursued this technique to introduce antibodies
to animal models for “vectored immunoprophylaxis” against HIV. This may be
conceptualized as an in vivo passive vaccination. Using the gene sequence of a broadly
neutralizing antibody to the human immunodeficiency virus (HIV) as a transgene, AAV
vectors were manufactured for intramuscular (IM) delivery. Muscle cells transduced by
the vector would produce the anti-HIV antibody constitutively. The antibody would
distribute into the circulatory system and throughout the body, thus conferring protection
from HIV infection. [114, 115]
In one report, HIV-susceptible humanized mice were injected intramuscularly
(IM) with an AAV vector containing a broadly-neutralizing HIV antibody transgene. The
full-length antibody was detected in mouse serum, and subsequent challenge with very
high doses of replication-competent HIV yielded no successful infection. A later report
described intramuscular administration in NHPs of 2e13 GC of an AAV vector with an
anti-simian immunodeficiency virus (SIV) antibody transgene. Subsequent IV challenge
with virulent SIV yielded no productive infection; all animals were completely protected.
[114, 115] Going forward, AAV delivery of antibodies thus shows promise for a variety of
gene therapy applications.
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CHAPTER 4
Human epidermal growth factor receptor 2 (HER2)
Human epidermal growth factor receptor 2 (HER2) is a 185 kDa membraneassociated tyrosine kinase that is expressed on cells throughout the body. It is one of
four members of the HER family of proteins which serve to transduce extracellular
growth signals and thus regulate cell survival and differentiation. HER2 has no known
ligand, unlike other members of the HER family of proteins which bind such ligands as
neuregulin (NRG) and extracellular growth factor (EGF, hence the more common name
of the HER1 protein, extracellular growth factor receptor or EGFR). Rather, the native
conformation of HER2 resembles that of other ligand-bound HER proteins. [116-124]
HER2 signal transduction begins with heterodimerization of ligand-bound
members of the HER family with HER2, the most potent combination of which is the
HER2/HER3 heterodimer. In normal cells, HER2 may homodimerize relatively
infrequently. These dimerization events lead to auto-phosphorylation and recruitment of
intracellular adapter proteins at the plasma membrane. This, in turn, leads to activation
of master regulators of cell growth and survival, including the phosphatidylinositol 3kinase/Akt (protein kinase B)/NFkB pathway and the mitogen-activated protein kinase
(MAPK) pathway. HER2 signal transduction is also associated with organogenesis
during fetal development and with tissue maintenance in adults. [116-124]
Overexpression of HER2 due to gene amplification is oncogenic. Cancer cells
that overexpress HER2 are termed HER2+ and may have up to 2- to over 20-fold more
HER2 expression than normal cells [125, 126]. As such, HER2 homodimerization occurs
more frequently in these cells, leading to greater ligand-independent growth signal
35

transduction. Several types of cancers may overexpress HER2 including breast,
stomach, uterine, and ovarian.
Breast cancers are of particular interest with respect to HER2 overexpression, as
approximately 20% of these cancers are HER2+, portending more aggressive disease
with a poorer prognosis than HER2- cancer. Whether or not a tumor is deemed HER2+
is determined either by a tumor HER2 IHC status of 3+ or greater, a HER2 gene copy
number of 6 or more by fluorescence in situ hybridization (FISH), or a HER2/CEP17 ratio
of greater than 210 by FISH on chromosome 17. [117, 118, 120, 125-133]

HER2 and trastuzumab (Herceptin®)
Trastuzumab was the first therapeutic monoclonal antibody to target HER2. It
was developed by Genentech, and in 1998 it was approved for first-line treatment of
metastatic HER2+ disease in combination with paclitaxel chemotherapy or as a secondor third-line agent by itself. In the 1980s, scientists at Genentech and the National
Cancer Institute discovered that HER2 overexpression was linked to breast cancer and
that cancers in which HER2 was overexpressed led to more aggressive disease, as
described above. [134] Genentech then developed a series of monoclonal antibodies
raised in mice against human HER2. One of these mouse anti-human HER2 IgGs,
termed 4D5, bound to the extracellular domain IV of HER2 and was able to suppress the
growth of HER2+human cancer cells both in vitro and in murine xenograft tumor models.
[118, 119, 135, 136]
To lessen the chance that 4D5 would induce an anti-mouse IgG immune
response in patients, it was humanized as described above in “Antibodies” in Chapter 3.
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Briefly, the antigen-binding portions of 4D5, including the CDRs, were inserted into the
framework of a human IgG1. The resulting “humab4D5-8” antibody is what is known
today as trastuzumab. Trastuzumab was found to bind to HER2+ cancer cells with a
dissociation constant of 0.1 nM. [118, 137, 138]
Trastuzumab has become part of the standard of care for patients with HER2+
primary and metastatic breast cancer. It is also approved for the treatment of HER2+
gastric cancer. Trastuzumab may be administered as adjuvant to chemotherapy,
meaning it is administered along with chemotherapy after surgery or radiation to reduce
the risk of recurrence or metastasis, or as neoadjuvant therapy, meaning as an agent
that is used to shrink a tumor before surgical resection. It is usually given at a loading
dose of 4 mg/kg body weight and at 2 mg/kg body weight for the duration of therapy.
This regimen maintains the trastuzumab serum trough concentration at around 10-20
µg/mL in serum. [127]
Many clinical trials were initiated beginning in the 1990s to evaluate trastuzumab
as an agent to treat HER2+ metastatic breast cancer, both as a single agent and along
with chemotherapy. To evaluate the safety of trastuzumab and its pharmacokinetics,
phase I clinical studies were conducted in patients with metastatic HER2+ breast cancer
refractory to treatment. In one study, patients were dosed IV either a single time or
weekly with 10-500 mg of trastuzumab along with cisplatin chemotherapy. No serious
adverse events (SAEs) related to trastuzumab administration were reported. A maximum
tolerated dose was not reached in this trial, and the half-life of trastuzumab in blood at
the 500 mg dose was determined to be 2 weeks. [118, 139]
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Phase II studies to evaluate the efficacy of trastuzumab were initiated with
trastuzumab as a single agent in patients with metastatic HER2+ breast cancer. The first
phase II trial involved 43 evaluable patients. The trastuzumab dose was 250 mg in the
first week and 100 mg every week subsequently for 10 weeks. One patient in this study
achieved a complete response to therapy for 6 years, and 4 patients achieved a partial
response. The combination of complete responders and partial responders represents
the overall response rate to treatment, in this study equal to 11.6%. 37% of the patients
experienced a minimal response to treatment, and disease progressed in the remaining
22 individuals. The median time to disease progression after initiation of therapy was 5.1
months [118, 138, 140, 141]
Another phase II study administered trastuzumab with cisplatin chemotherapy to
39 patients with HER2+ metastatic breast cancers that were treated with previous
chemotherapy but had relapsed. The dose of trastuzumab was the same as the singleagent phase II trial above. There were 37 evaluable patients in this trial. Though none
had a complete response, 9 patients experienced a partial response. 3 patients had a
minor response. Disease stabilized in 6 patients and progressed in 19 patients. The
overall response rate was thus calculated to be 24.3%. The median survival was 11
months, and the median response duration was 5.3 months. [118, 138]
The largest phase II trastuzumab clinical trial was an open-label, single-arm
study conducted across 54 centers. 222 patients were included who had been treated
with one or two previous cytotoxic chemotherapy regimens but in whom disease had
relapsed. In this trial, trastuzumab dose was calculated based on body weight of the
patients at a 4 mg/kg loading dose (first dose) and a 2 mg/kg maintenance dose
(subsequent doses). Patients also received chemotherapy in the form of doxorubicin or
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epirubicin plus cyclophosphamide or, if patients had already received anthracycline
chemotherapy, paclitaxel. Of 204 evaluable patients, eight achieved a complete
response and 26 achieved a partial response. The overall response rate was calculated
to be 15%. 12 patients had a minimal response to trastuzumab treatment and 62 had
stable disease. The rest of the patients experienced disease progression. The median
duration of response to therapy was determined to be 9.1 months, and median survival
was 13 months.
Interestingly, patients whose disease showed greater HER2 overexpression by
immunohistochemistry responded better to trastuzumab therapy in this trial. Average
serum trastuzumab peak and trough concentrations among all patients were calculated
to be 100.3 µg/mL and 25 µg/mL, respectively. Mean trough trastuzumab concentrations
in patients with complete responses were higher at weeks 7 and 8 of therapy (70.3
µg/mL) as opposed to serum trastuzumab concentration in patients with partial
responses (54.8 µg/mL). The half-life of trastuzumab in this study was calculated to be
6.2 days. [118, 138, 142]
Following these phase I and II studies, phase III randomized, placebo-controlled,
multi-center trials were conducted in over 900 women with HER2+ metastatic disease. In
the pivotal phase III trial, 469 patients were included with a median follow-up time of 29
months. These women had received prior chemotherapy. The trastuzumab dose was 4
mg/kg in the first week followed by 2 mg/kg in subsequent weeks. More patients who
received trastuzumab plus chemotherapy in this trial were still living one year after
initiation of treatment (79%) compared to women who received chemotherapy only
(68%). Patients who received trastuzumab also had a significantly longer median
survival, 25.4 months compared to 20.3 months in patients who received chemotherapy
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alone. The approximate increase in median survival was calculated to be 25%. Time to
disease progression was longer in patients in the trastuzumab arm of the trial, 7.6
months compared with 4.6 months in the chemotherapy arm. The overall response rate
was higher in patients who received trastuzumab and chemotherapy, 49% compared to
32% in patients who received chemotherapy alone. [143-145]
Further phase III trials were conducted in over 3500 patients with operable, node
positive HER2+ breast cancer. These studies compared treatment with 1 year of
adjuvant trastuzumab plus chemotherapy (doxorubicin plus cyclophosphamide followed
by paclitaxel) to chemotherapy alone. When analyzed together, the studies indicated
that patients who received adjuvant trastuzumab in addition to chemotherapy
experienced recurrence of their tumors at a 52% lower rate than patients who received
chemotherapy alone. The risk of death after 24 months of follow-up was calculated to be
33% lower in patients in the trastuzumab arm. [146]
Even after metastatic HER2+ breast cancer progresses, trastuzumab treatment
has been shown to extend median overall survival as demonstrated in five randomized
clinical trials (114, 118-123). Additionally, a study of 247 patients who continued to
receive trastuzumab after disease progression found it to be well-tolerated without
increased incidence of adverse events such as cardiotoxicity (170).
Following the approval of trastuzumab by the FDA in 1998, the repertoire of
targeted treatments for HER2+ cancer has continued to expand. One of these drugs is a
modified trastuzumab treatment called trastuzumab emtansine (Kadcyla). Kadcycla is
trastuzumab conjugated to the cytotoxic agent emtansine (DM1), an inhibitor of
microtubule assembly. Trastuzumab emtansine takes advantage of the ability of
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trastuzumab to home to cells that overexpress HER2, allowing for localized, effectively
concentrated delivery of emtansine to tumors.
In clinical trials of Kadcyla, patients with locally advanced or metastatic breast
cancer previously given trastuzumab and chemotherapy were included. A median
survival was not reached in patients who received trastuzumab emtansine, but a median
survival of 23.3 months was reported in patients that received a chemotherapeutic
regimen of capecitabine and lapatinib (described below). The overall response rate in
patients that received trastuzumab emtansine was 43.6% as opposed to 30.8% of
patients who received chemotherapy. [147]
Another HER2-targeted agent is the monoclonal antibody pertuzumab.
Pertuzumab works synergistically with trastuzumab, binding to the extracellular domain
of HER2 to disrupt HER2/HER3 dimerization. In patients with operable HER2+ breast
cancer, adding pertuzumab to trastuzumab therapy increases the duration of diseasefree survival.[148]
Finally, lapatinib is a small molecule inhibitor of HER1 and HER2, targeting the
intracellular domain of these proteins. It is used to treat patients with metastatic HER2+
breast cancer and is discussed further in Chapter 6 “HER2+ breast cancer brain
metastases.”
The mechanisms of action of trastuzumab
Therapeutic monoclonal antibodies targeted against cancer may exert their
effects in many different ways. The first FDA-approved monoclonal antibody developed
against cancer, rituximab, was shown to work mainly by activation of the complement
cascade, leading to tumor cell lysis. However, its other mechanisms of action have been
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elucidated in the literature, including interruption of cell signaling and immune cellmediated cytotoxicity. [149]. The various methods by which trastuzumab exerts its antitumor activity have also been extensively studied.
The main mechanism of action of trastuzumab is mediating a process called
antibody-dependent cell-mediated cytotoxicity (ADCC). Trastuzumab bound to HER2 on
a tumor cell is engaged by an NK cell possessing an activating FcR, such as FcγRIIIa.
The activating FcR binds to the Fc portion of trastuzumab, inducing the NK cell to
release cytotoxic proteins such as perforins, which form holes in the tumor cell
membrane, and granzymes, proteases which activate apoptosis of the targeted cell,
leading to tumor cell death. Other immune cells such as macrophages also possess
activating Fc receptors and can undergo antibody-dependent cell-mediated
phagocytosis (ADCP), a process by which the macrophage devours the trastuzumabdecorated tumor cell. In vivo, NK cells are the main effector cells governing trastuzumabmediated cytoxicity.[150]
Several studies have demonstrated that trastuzumab mediates ADCC both in
vitro and in vivo. In 2001, Clynes et al. reported failure of trastuzumab treatment to arrest
growth of HER2+ xenografted tumors both in nude mice lacking activating FcRs and in
mice treated with an antibody to disrupt Fc binding to FcRs. It was determined that an
activating FcR is necessary for trastuzumab to exert an anti-tumor response. [151]
Gennari et al. studied peripheral blood mononuclear cells (PBMCs) from breast
cancer patients treated with trastuzumab as a single agent in the neoadjuvant setting,
with surgical resection of tumor 7 days after trastuzumab administration. In vitro ADCC
assays were performed using patient serum from before or after trastuzumab treatment
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applied to HER2+ target cells. This was followed by application of autologous PBMCs. In
most patients who had received trastuzumab therapy, there was significant killing of
HER2+ target cells by autologous PBMCs. Interestingly, using PBMCs from patients with
a better clinical response to trastuzumab therapy led to a higher degree of tumor cell
death in vitro. Additionally, tumor samples from patients treated with trastuzumab were
unable to be stained histologically by trastuzumab conjugated to horseradish peroxidase
(HRP), suggesting that available antigen binding sites on the tumor cells were saturated
by already-bound trastuzumab [152].
Arnould et al. used histology techniques to study immune cell infiltrates in tumor
samples of patients also treated with trastuzumab in the neoadjuvant setting. 23 patients
who received trastuzumab and docetaxel for 17 weeks underwent surgical resection of
the primary tumor after the last cycle of combined trastuzumab and docetaxel treatment.
Case-matched controls received docetaxel without trastuzumab. Pathologists analyzed
tumor slides for the presence of B cells, T cells, macrophages, dendritic cells, and NK
cells. Trastuzumab treatment resulted in an increase in the number of NK cells
associated with the tumor and increased expression of granzymes and TiA1, a proapoptotic protein, in tumor-infiltrating lymphocytes. [153]
Trastuzumab has been shown to exert its anti-tumor effect by other mechanisms
as well. Trastuzumab blocks homodimerization of the HER2 protein, preventing signal
transduction and leading to inhibition of pathways associated with cell survival. For
example, when tumor cells are exposed to trastuzumab in vitro, MAPK and PI3K/AKT
cell growth-associated pathways are downregulated. [150, 154, 155]
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Trastuzumab has also been shown to prevent cleavage of the extracellular
domain of HER2 on tumor cells, which occurs normally and is mediated by 5aminophenymercuric acetate matrix metalloproteinase activator. The remaining p95
membrane-associated protein is able to transduce growth signals by itself. [155-157]
Trastuzumab has also been shown to inhibit tumor-associated angiogenesis.
Tumors normally secrete vascular endothelial growth factor (VEGF), and increased
VEGF expression is associated with HER2 overexpression. In a xenograft model,
trastuzumab administration led to decreased tumor vascularization as well as
normalization of tumor vascular permeability, diameter, and volume. VEGF mRNA
expression was also decreased in trastuzumab-treated tumor cells in this experiment.
[158]
Finally, HER2 signaling is important for activating DNA repair pathways. Treating
cancer cells with trastuzumab downregulates these DNA repair pathways. Studies by
Pietras et al. in 1998 and 1999 in murine xenografts showed a 35-40% reduction of
cisplatin-induced DNA damage in vivo after trastuzumab treatment as well as prevention
of a slow S phase necessary for tumor cells to repair radiation-induced DNA damage
[159, 160].

Trastuzumab-related cardiotoxicity
A small number of patients who received trastuzumab in the pivotal phase III
clinical trial described above developed cardiac dysfunction. Those who received
concurrent anthracycline chemotherapy, such as doxorubicin (Adriamycin) were
particularly affected. 27% of patients who received trastuzumab plus an anthracycline
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developed systolic dysfunction compared with 8% of patients who received an
anthracycline alone.
At first, it was believed that the combination of trastuzumab and anthracyclines
led to this cardiac dysfunction. However, endomyocardial biopsies of patients with
trastuzumab-associated cardiotoxicity did not show the same ultrastructural changes
known prior to be associated with anthracycline-associated cardiotoxicity. The dose of
trastuzumab that a given patient received also did not correlate with the development of
cardiotoxicity. Later studies conducted in patients without previously diagnosed
cardiovascular disease who did not receive anthracyclines simultaneously with
trastuzumab still reported cases of cardiotoxicity. In these reports, the risk of
trastuzumab-associated heart failure was 3.9%. [116, 161-163]
Although the exact mechanism of trastuzumab-induced cardiotoxicity is not fully
understood, scientists have discovered that cardiomyocytes require some baseline level
of HER2 signaling for normal function [161]. Mouse models were developed with
conditional knock-outs of HER2 and HER4 in ventricular tissue. By 8-12 weeks of age,
these mice had already developed dilated cardiomyopathy, and the cardiomyocytes of
these mice were more susceptible to anthracycline-induced death. NRG, which binds to
HER4, was found to play a large role in the recovery of cardiomyocytes after stress.
HER2 signaling was also suggested to be involved in formation and maintenance of the
conduction system of the heart, contractility, regulating myofilament architecture,
glucose metabolism, and angiogenesis. [162, 164-168]
Extensive research has been performed to determine a patient’s risk for
developing trastuzumab-associated cardiotoxicity. A 2012 meta-analysis of multiple
45

large clinical trials (11,911 women total) indicated that trastuzumab treatment was
associated with an increased risk for severe heart failure (2.5 vs. 0.4%) and a reduction
in left ventricular ejection fraction (LVEF), a measure of heart function. This
trastuzumab-associated reduction in LVEF manifests asymptomatically in the majority of
patients who experience it. [169]
The National Adjuvant Breast and Bowel Project (NSABP) B31 7-year follow-up
found that patients who received trastuzumab had a 4% 7-year cumulative risk of a
cardiac event compared to a 1.3% cumulative risk for patients who did not receive
trastuzumab. A cardiac event was defined as definite or probable cardiac death, heart
failure (dyspnea with normal activity or at rest) with an LVEF decline of greater than 10%
from baseline, or an LVEF of <55%. [170]
The Herceptin Adjuvant Trial (HERA, BIG1-01) 8-year follow-up compared
patients who received 2 years of trastuzumab (n=1673), 1 year of trastuzumab (n=1682),
or observation (n=1744). Congestive heart failure was reported in 0.8%, 0.8%, and 0%
of patients, respectively. A significant LVEF decrease was reported in 7.2%, 4.1%, and
0.9% of these patients, respectively. Severe congestive heart failure and cardiac death
were found to be rare in all study arms. Of patients who experienced a significant
decrease in LVEF, acute recovery was reached in 87.5% of patients who received 2
years of trastuzumab treatment and 81.2% of patients who received 1 year of
trastuzumab treatment. [171]
Another phase III trial reported that 33 patients who developed a cardiac event
(most often an asymptomatic decline in LVEF) continued trastuzumab treatment. 85% of
these patients’ cardiac function eventually improved or remained the same. This study
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also found that 75% of patients with symptomatic cardiotoxicity experienced reversal of
symptoms when treated with standard heart failure therapy (including, but not limited to,
angiotensin converting enzyme inhibitors, aldosterone antagonists, angiotensin receptor
blockers, or beta blockers) [161].
A retrospective review of 49 patients with trastuzumab cardiotoxicity drew similar
conclusions. In this study, 79% of patients who experienced cardiotoxicity subsequently
recovered with appropriate heart failure therapy and withdrawal of trastuzumab. Of these
patients, 26 resumed trastuzumab treatment. Only 10 patients developed cardiac
dysfunction again, and 5 of these patients continued to receive trastuzumab therapy,
with a slight decrease in LVEF as the only indication of cardiotoxicity. [172]
In another study, risk factors associated with trastuzumab cardiotoxicity were
found to be patient age greater than 50 years, previous or concurrent use of
anthracycline chemotherapy, preexisting cardiac dysfunction, and overweight (>30) body
mass index. Antihypertensive therapy, diabetes, valvular heart disease, and coronary
artery disease were not found to increase the risk of cardiotoxicity [173].
Other HER2-targeted chemotherapies have also been reported to cause
cardiotoxicity. Pertuzumab is another monoclonal antibody that targets a different
epitope of HER2 than trastuzumab, and it is often co-administered with trastuzumab. In
the CLEOPATRA trial, 8.3% of patients who received placebo, trastuzumab, and
docetaxel experienced decreased LVEF compared with 4.4% who received pertuzumab,
trastuzumab, and docetaxel. The cardiotoxicity of lapatinib has also been studied. A
meta-analysis of 49 trials in (n=3689 patients total) concluded that 1.4% of patients who
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received lapatinib experienced asymptomatic cardiac events and 0.2% of patients
experienced congestive heart failure. [173]
In summary, trastuzumab cardiotoxicity occurs in a small but significant
percentage of patients treated with trastuzumab. The exact percentage varies depending
on the study but ranges from less than 1% to about 10%. In the majority of these
patients, cardiotoxicity manifests as an asymptomatic decline in LVEF, with many fewer
developing fulminant heart failure. The occurrence of cardiotoxicity is not related to the
dose of trastuzumab that patients receive. Instead, cardiotoxicity is more likely to occur if
a patient received or is receiving anthracycline chemotherapy or if they have preexisting
cardiac dysfunction such as a low baseline LVEF. Older and overweight individuals are
also at higher risk for developing cardiotoxicity. Most patients who experience
cardiotoxicity recover baseline cardiac function after trastuzumab is withdrawn and/or
standard heart failure drugs are administered. A large subset of the patients who
experience trastuzumab cardiotoxicity will resume trastuzumab treatment and
experience no further cardiac episodes. The mechanism of cardiotoxicity is not fully
understood, but it known that HER2 signaling is linked to cardiomyocyte survival.
Importantly, studies have shown that long-term administration of trastuzumab is
generally well-tolerated.
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CHAPTER 5
HER2+ breast cancer brain metastases (BCBM)
Compared to other subtypes of breast cancer, HER2+ disease has the second
poorest overall prognosis, tends to be more aggressive, and has a higher propensity to
metastasize to other organs, including the brain [119, 125]. Brain metastases are a
devastating sequela of HER2+ breast cancer, with reports indicating an incidence of 1535.2% among patients with HER2+ disease compared to 10-16% of patients with any
type of breast cancer. [129, 174-193] Interestingly, autopsies of patients with any type of
breast cancer and no clinical evidence of brain metastases have found that up to 30% of
patients have pathologically evident metastases or micrometastases at death [161, 194196]. 80% of brain metastases are detected after the diagnosis of systemically
metastatic disease. There is a 75% chance that if primary breast tumor is HER2+, brain
metastases will also be HER2+. [127, 128, 197]. In most retrospective studies of patients
presenting with breast cancer brain metastases (BCBM), CNS disease was discovered
after clinical reports of headache or neurological deficits due to the mass effect of brain
tumors. [194]
Approximately 17,000 women every year will be diagnosed with HER2+ BCBM in
the US, and the median survival of these patients will be 10-13 months from the time of
diagnosis [174], although the RegistHER prospective observational study results
published by Brufsky et al report a median survival of 17.5 months [198]. Other studies
indicate that only 20% of HER2+ BCBM patients will be alive a year after diagnosis of
CNS disease and that these patients these patients tend to be younger (less than 50
years old) and have 2 or more metastatic foci outside of the CNS [198-200]. A reported
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41-52% of patients die as a result of BCBM progression as opposed to other causes
including progression of systemically metastatic disease. [174, 194, 198, 201-204]
A small percentage of patients with HER2+ BCBM will present with
leptomeningeal carcinomatosis (LC), a rare type of brain metastasis with that accounts
for 5% of patients with HER2+ BCBM [181, 204, 205]. In LC, tumor cells cloak the brain,
spreading along the leptomeninges, a term that refers to the pia and arachnoid mater,
which are membranous coverings of the brain between which flows CSF. Patients with
LC have an even poorer prognosis than those with focal metastases, with median overall
survival ranging from 2 to 5.2 months from the time of LC diagnosis. Most patients
survive less than a year from the time of LC diagnosis. [204-209]
Current treatments for HER2+ BCBM do not confer substantial survival benefit.
The presence of the BBB excludes many chemotherapeutics and biological therapies
that are used successfully to treat systemically metastatic disease, including anti-HER2
monoclonal antibodies such as trastuzumab. The standard of care for patients with
HER2+ BCBM depends on the number of tumor foci or whether the patient has LC.
Patients with one or a limited number of focal metastases will typically undergo
neurosurgical resection of their tumor(s) along with systemically-administered
chemotherapy and/or trastuzumab plus pertuzuamb, despite the poor penetration of
these treatments into the CNS [198]. A response to single-agent IV trastuzumab therapy
is only seen in 11-15% of patients with HER2+ BCBM [140, 210].
If feasible, stereotaxic radiosurgery, a high-energy type of focused radiation
therapy, may be used against HER2+ BCBM, particularly in patients with a limited
number of metastases or for whom surgical resection is contraindicated. If stereotaxic
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radiosurgery is not available or if surgical resection is impossible, patients with multiple
metastases will undergo whole brain radiation therapy, which can improve survival and
reduce the frequency of intracranial relapse from 80% to 50% [185]. However, whole
brain radiation therapy can carry a set of side effects including decreased IQ, cognitive
deficits, urinary incontinence, and dementia [211]. Neither radiation treatment nor
chemotherapy improves prognosis for patients with leptomeningeal disease [186, 193,
206]. All too often, patients with systemically metastatic HER2+ disease receiving
therapies including intravenous trastuzumab therapy will experience regression in
visceral disease in response to treatment while CNS disease simultaneously progresses.
[211]
Patients with HER2+ primary or systemically metastatic disease treated with
trastuzumab are at higher risk for developing brain metastases. This was discovered as
a result of post-hoc anslysis of clinical trials including the NSABP B-31 and HERA
studies mentioned above. In these trials, CNS metastases were recorded more
frequently in patients who received trastuzumab therapy as opposed to control
treatments.
A few factors have been postulated to account for the increased incidence in
HER2+ BCBM over the past several decades among patients who have received
trastuzumab to treat visceral disease. The increasing efficacy of chemotherapeutic
regimens and anti-HER2 agents to treat systemically metastatic HER2+ breast cancer
and the corresponding increase in overall survival for these patients may allow time for
the outgrowth of brain metastases that in the past may have remained undetectable
before death. Additionally, poor penetration of trastuzumab into the CNS due to its size
and thus a lack of HER2 blockade in HER2+ tumor deposits that are unappreciable
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clinically or by imaging modalities may contribute to the increasing incidence of HER2+
BCBM. [129, 174, 177, 186, 193, 194, 198, 212]
For patients with HER2+ BCBM, the small molecule lapatinib offers some clinical
benefit. Lapatinib is an inhibitor of HER1 and HER2, targeting the intracellular domain of
these proteins. In the LANDSCAPE phase II trial, which included patients with HER2+
BCBM that were previously untreated, 65.9% of patients experienced a partial response
to lapatinib plus capecitabine. However, one phase III trial, called CEREBEL, studied the
effect of lapatanib on the incidence of CNS metastases in patients with HER2+
systemically metastatic disease who did not yet have CNS metastases. Patients were
treated either with lapatinib plus capecitabine or trastuzumab plus capecitabine. The
study did not find a significant difference between the two treatment regimens in terms of
incidence of CNS disease, progression-free survival, or overall survival. Other phase III
studies with lapatinib are ongoing as of October 2017. [213, 214] Additional small
molecule inhibitors of HER2 which may cross the blood-brain barrier to target HER2+
brain metastases are in development [215].

Intrathecal trastuzumab as HER2+ BCBM treatment
When administered IV, trastuzumab penetrates poorly into the CNS. Pestalozzi
et al. illustrated this point in 2000, describing weekly IV trastuzumab administration in a
patient with LC. On week one, a loading dose of 240 mg was administered. The
following week, 120 mg trastuzumab was administered, and the patient’s serum and
CSF were collected for ELISA. The trastuzumab concentration was determined to be
61.392 µg/mL in serum and 0.210 µg/mL in CSF. Another week later, another 120 mg
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trastuzumab was administered again, and serum and CSF were collected for ELISA.
Serum trastuzumab was measured to be 70.336 µg/mL and CSF trastuzumab to be
0.212 µg/mL [216]. This phenomenon is not limited to humans. In a preclinical study in
mice by Abukayyas et al., a radio-labeled human IgG1 antibody was administered
intravenously. The resulting brain-to-blood ratio of IgG in was determined to be 0.7%.
[217, 218]
Because IV trastuzumab does not cross the BBB effectively, many clinicians
have administered trastuzumab intrathecally to patients with HER2+ BCBM “off-label.”
Table 1, found in Chapter 6, lists case reports of patients with HER2+ BCBM, either LC
or intraparenchymal disease. The table includes trastuzumab dose, dose frequency,
indicated concurrent treatments, degree of clinical response, duration of response,
adverse events (AEs) or serious adverse events (SAEs), and overall survival. For most
of these patients, IT trastuzumab provides some clinical benefit. No AEs or SAEs have
been reported related to IT trastuzumab administration.
To examine the significance of the clinical benefit of IT trastuzumab, Zagouri et
al. conducted a meta-analysis in 2013 of patients with LC who received IT trastuzumab
treatment. The analysis concluded that overall survival increases from 5.9 months in
historical controls to 13.5 months in patients who received IT trastuzumab. Additionally,
68.8% of patients experienced significant clinical improvement. [219]
Two case reports have reported that IT trastuzumab can provide clinical benefit
to patients with intraparenchymal disease. Bousquet and colleagues gave IT
trastuzumab to a patient with HER2+ cerebellar and epidural breast cancer metastases,
resulting in a six-month halt in disease progression [220]. Colozza and colleagues
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describe a patient with HER2+ intraparenchymal cortical metastases who was treated for
19 months with IT trastuzumab [221]. Both patients were still alive at the time of
publication.
As a result of these successful reports, several clinical trials have been initiated
to examine the effect of IT trastuzumab in patients with LC. Table 2 in Chapter 6 lists
these ongoing trials, compiled from clinicaltrials.gov. Of note, IT trastuzumab is dosed in
these trials within the range of 30-150 mg per administration. Interestingly, trastuzumab
is not the only monoclonal antibody to show promise after IT administration for CNS
malignancy. Rituximab administered IT has been tested in two phase I clinical trials and
has shown benefit for patients with CNS B cell lymphoma [222, 223]. The anti-epidermal
growth factor receptor (EGFR) antibody panitumumab has also administered to single a
patient with EGFR mutant lung adenocarcinoma that metastasized to the brain [224].
Although IT trastuzumab has shown promise, it is likely that the normal, rapid
clearance of CSF compromises the efficacy of IT trastuzumab. In a study by Braen et al.,
cynomolgus macaques were given 3mg or 15mg trastuzumab by intrathecal infusion,
with 3 macaques in each dose group. The mean concentration of trastuzumab in CSF in
the 3 mg dose cohort one day after trastuzumab infusion was around 10,000 ng/mL.
One week after infusion, the trastuzumab concentration in CSF was around 50 ng/mL. In
the 15 mg dose cohort, the mean concentration of trastuzumab in CSF one day after
infusion was around 20,000 ng/mL, and one week after infusion, the trastuzumab
concentration was around 200 ng/mL [225].
In the report by Bousquet et al where IT trastuzumab was administered to a
patient with HER2+ cerebellar and epidural BCBM, the half-life of trastuzumab in CSF
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was calculated to be around 12 hours. The half-life of trastuzumab in blood has been
calculated by multiple studies. These include a trastuzumab half-life of 8.3 days after a
100 mg IV dose in 45 patients [140], 28.5 days after a 2 mg/kg IV dose in 476 patients
[226], and 6 mg/kg after the 12th IV dose in 15 patients [227]. Of note, the clinical trial
conducted by Gutierrez et al. listed in Table 2 aims to achieve a CSF trastuzumab
concentration of 30 µg/mL to maximize potential therapeutic effect.
In summary, HER2+ BCBM are a devastating diagnosis that leave patients with
few options for treatment. IT administration of trastuzumab has shown promise in
several case reports, and clinical trials are being conducted to evaluate its efficacy in an
official setting. Still, it is possible that combining an intrathecal trastuzumab treatment
approach with AAV gene therapy techniques may improve survival for patients with
HER2+ BCBM. It is also conceivable that an IT AAV gene therapy to express
trastuzumab behind the BBB may serve as prophylaxis for patients with systemically
metastatic HER2+ disease at risk for developing CNS disease.
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CHAPTER 6
Intrathecal AAV9.trastuzumab tumor prophylaxis and treatment in a murine
xenograft model of HER2+ breast cancer brain metastases
Introduction
Breast cancer is the most commonly diagnosed malignancy in women in the US
with an estimated 252,710 new cases in 2017 [228]. Approximately 20% of breast
cancers overexpress HER2 and are considered to be more aggressive and more likely
to metastasize to the brain than other breast cancer subtypes [175, 191, 229]. About
30% of patients with metastatic HER2+ breast cancer will develop BCBM [174, 178, 193,
230]. The registHER prospective study of patients with newly-diagnosed HER2+
metastatic breast cancer found that 37.3% of the 1012 patients studied developed brain
metastases within 10.8 months from the initial diagnosis of metastatic disease [198].
Brain metastases can significantly lower patient quality of life by inducing nausea,
sensory loss, aphasia, motor deficits, ataxia, seizures, stroke, and paralysis [175, 231233]. The median age at diagnosis of HER2+ BCBM is 48 years [234], and the incidence
of HER2+ BCBM is rising [191]. It has been suggested that this increase is due to many
factors. Targeted, effective therapies for HER2+ tumors in the periphery have increased
the duration of patient survival, thereby allowing adequate time for outgrowth of brain
metastases that would have otherwise remained subclinical before death [231, 235].
Many of these therapies, including biological therapeutics, do not reach adequate
concentrations in cerebrospinal fluid (CSF) after systemic administration [216, 236].
Current standard of care treatments for HER2+ BCBM are invasive, can cause
cognitive impairment, and provide suboptimal survival benefit. Patients often undergo a
combination of neurosurgical tumor resection, stereotaxic radiosurgery, whole brain
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radiation therapy, systemic and/or intrathecal chemotherapy, steroids, or anti-HER2
agents [175, 231, 235]. Even with these treatments, survival from the time of diagnosis
of HER2+ BCBM ranges from 3 to 25 months with a median of 10-13 months [174, 188,
198, 237]. Clearly, there is an unmet need for more effective, targeted treatments for
patients with HER2+ BCBM.
Trastuzumab (Herceptin®, Roche) is a humanized monoclonal antibody (mAb)
directed against HER2 that extends survival of patients when used with chemotherapy to
treat primary and systemically metastatic HER2+ disease [174, 210, 238]. However,
trastuzumab does not cross the intact blood-brain barrier to treat central nervous system
(CNS) tumors [175, 229]. Additionally, the CSF concentration of trastuzumab after
intravenous (IV) administration is 300 to 400-fold lower than in serum [216, 236]. As
such, patients with concurrent HER2+ BCBM and systemic HER2+ disease who receive
IV trastuzumab often experience regression or stabilization of systemic tumor burden
while brain metastases progress [174].
Trastuzumab administered IT has been reported to increase survival and delay
progression of HER2+ brain metastases. Bousquet and colleagues gave IT trastuzumab
to a patient with HER2+ cerebellar and epidural breast cancer metastases, resulting in a
six-month halt in disease progression [220]. Colozza and colleagues describe a patient
with HER2+ intraparenchymal cortical metastases who was treated for 19 months with IT
trastuzumab [221]. In both case reports, patients were still alive at the time of
publication. A 2013 meta-analysis by Zagouri and colleagues demonstrated that the
median survival of patients with HER2+ leptomeningeal carcinomatosis (LC), a
particularly deadly form of BCBM, increases from 5.9 months in historical controls to
13.5 months with IT trastuzumab treatment [219].
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Despite these promising reports, IT administration of trastuzumab has
disadvantages. Multiple intrathecal administrations are required. Perhaps more
importantly, the normal, rapid turnover of cerebrospinal fluid (CSF) results in a widelyfluctuating pharmacokinetic profile of trastuzumab in CSF, resulting in a CSF half-life of
just 12 hours in one case report [220, 239]. It is therefore unlikely that tumor cells in the
CNS receive optimal exposure to trastuzumab after IT administration.
Gene therapy offers the potential for a one-shot solution to the problem of mAb
delivery across the blood-brain barrier. Adeno-associated viral (AAV) vectors,
particularly serotype 9, can safely and efficiently deliver exogenous genes, such as the
gene for trastuzumab, to neurons and astrocytes throughout the brain and spinal cord
after a single IT administration. This results in long-term, stable expression of the
transgene product in the brain parenchyma and CSF [49, 56].
We aim to use AAV9.trastuzumab delivered IT to bypass the blood-brain barrier
for localized expression of trastuzumab in situ. Using a Rag1-/- murine orthotopic
xenograft model of HER2+ BCBM, we delivered AAV9.trastuzumab IT by
intracranioventricular (ICV) injection either as tumor prophylaxis or as tumor treatment.
In both cases, a single dose of IT AAV9.trastuzumab significantly extended median
survival of mice compared to no treatment or control AAV vector treatment. Looking
ahead, we predict that IT AAV9.trastuzumab could prolong survival of patients with
existing HER2+ CNS metastases in addition to patients with primary or metastatic
HER2+ breast cancer at risk for developing BCBM.
Hypotheses
Using an orthotopic murine xenograft model of human HER2+ BCBM, we aimed
to express trastuzumab in the CNS by administering AAV9.trastuzumab IT by way of
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ICV injection. Vector was administered as tumor prophylaxis 21 days before tumor
implantation or as tumor treatment 3 days after tumor implantation. In both the
prophylactic and treatment setting, we expected mice that received AAV9.trastuzumab
to survive longer than mice that received an AAV9 vector to express an irrelevant
antibody or mice that received no treatment.
The main mechanism of action by which trastuzumab exerts its anti-tumor effect
in vivo is by mediating ADCC of tumor cells, chiefly by NK cells. We sought to
demonstrate that this primary mechanism of action was preserved in our model and in
the CNS compartment. When an NK cell depleting agent was administered systemically,
we expected the median survival of mice that received AAV9.trastuzumab tumor
prophylaxis to decrease compared to mice that received AAV9.trastuzumab tumor
prophylaxis without the NK cell depleting agent. Given that macrophages may perform
ADCP on tumor cells, we also hypothesized that depleting macrophages in the systemic
compartment of mice that received AAV9.trastuzumab tumor prophylaxis would lead to a
shorter median survival than mice given AAV9.trastuzumab tumor prophylaxis without
macrophage depletion.
Results
IT AAV9.trastuzumab provides tumor prophylaxis and treatment in a xenograft model of
HER2+ BCBM
We first tested AAV9.trastuzumab as HER2+ CNS tumor prophylaxis in our
Rag1-/- xenograft model. No treatment, AAV9.trastuzumab, or AAV9.2.10AmAb (a
negative control vector expressing a rhesus anti-simian/human immunodeficiency virus
IgG) were administered IT by ICV injection at least 21 days before tumor implantation.
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HER2+ BT474-M1.ffluc cells (100,000) were implanted in the brain parenchyma
stereotaxically, and mice were monitored daily until moribund. Kaplan-Meyer survival
curves (Fig. 1A-B) indicate that the median survival of mice that received IT
AAV9.trastuzumab tumor prophylaxis was significantly greater than mice that received
AAV9.2.10AmAb (124 days vs 46.5 days; p<0.0001, hazard ratio = 0.0306). The median
survival of mice that received AAV9.2.10AmAb was not significantly different from mice
without treatment (46.5 days vs 50 days; p=0.4306, hazard ratio = 1.1868). Protein A
ELISA quantification of IgG transgene expression in serum (Fig. 1C-D) and brain tissue
homogenate, normalized to total protein in brain homogenate (Fig. 1E), indicates that
transgene expression was similar between groups that received AAV9.trastuzumab and
AAV9.2.10AmAb. Tumors remained HER2+ at the time of necropsy (Fig. 1F).
Biodistribution analysis of AAV9 vector genome copies in brain tissue demonstrates
equivalent genome deposition between groups that received vector (Fig. S1).
To determine if IT AAV9.trastuzumab can serve as treatment for existing HER2+
BCBM, we implanted HER2+ BT474-M1.ffluc tumors in Rag1-/- mice and administered
IT AAV9.trastuzumab or no treatment three days after tumor implantation. Kaplan-Meyer
survival curves (Fig. 2) indicate that the median survival of mice that received
AAV9.trastuzumab (82 days, p=0.002) is significantly greater than mice that received no
treatment (61 days).
To compare the amount of trastuzumab in brain tissue after ICV administration of
AAV9.trastuzumab versus Herceptin®, 1e11 GC AAV9.trastuzumab or 15 µg
Herceptin® were administered ICV to Rag1-/- mice. Assuming a mouse brain mass of
0.4g, the 15 µg trastuzumab dose is equivalent to 37.5 µg trastuzumab/g brain mass.
This dose would be the equivalent of a 50.625 mg dose of trastuzumab in a 1350 g
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human brain. Brains from mice that received AAV9.trastuzumab were harvested 2
weeks after vector administration, while brains that received Herceptin® were harvested
24, 48, and 168 hours after antibody administration. Fig. S2 indicates that the median
amount of trastuzumab expressed in brains tissue in mice that received
AAV9.trastuzumab is slightly higher than the amount of Herceptin® in brain tissue 24
hours after administration of 15 µg antibody. Over time, the amount of Herceptin® in
brain tissue decreases, as expected.

Prophylactic IT AAV9.trastuzumab slows tumor growth
To determine if IT AAV9.trastuzumab tumor prophylaxis slows tumor growth, we
measured tumor diameter 47 days after implantation. The median diameter of tumors
from mice that received AAV9.trastuzumab tumor prophylaxis (1.2 mm, n=5) was
significantly smaller than mice that received AAV9.2.10AmAb (5.7 mm, n=5) or no
treatment (7.2 mm, n=4) (Fig. 3A). Transgene expression in brain tissue and in serum
collected before tumor implantation shows higher but comparable median 2.10A mAb
expression (Fig. 3B-C).

Secreted trastuzumab binds to HER2+ brain tumors
Anti-IgG immunofluorescence of day 47 tumor cryosections was employed to
determine if secreted trastuzumab could bind to HER2+ tumor cells in vivo. Micrographs
show trastuzumab decorating tumors from mice that received IT AAV9.trastuzumab but
not tumors from mice that received IT AAV9.2.10AmAb or no treatment (Fig. 3D,
overexposures Fig. S3A). Additionally, neurons transduced by AAV9.trastuzumab or
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AAV9.2.10AmAb stain positive for IgG. Secreted trastuzumab also decorated day 20
tumors from mice that received AAV9.trastuzumab (Fig. S3B). Tumors remain HER2+
on the day of necropsy (Fig. S5).

NK cells, but not macrophages, mediate IT AAV9.trastuzumab tumor prophylaxis
Trastuzumab exerts its effect against peripheral tumors mainly by facilitating
antibody-dependent cell-mediated cytotoxicity (ADCC) of HER2+ tumor cells [120, 151,
240]. We hypothesized that the same mechanism would govern AAV9.trastuzumab
tumor prophylaxis in the CNS. We first evaluated AAV9.trastuzumab tumor prophylaxis
in NOD scid gamma (NSG) mice, which lack NK cells and functional macrophages. As
expected, AAV9.trastuzumab tumor prophylaxis fails in NSG mice (Fig. 4). Survival was
comparable between groups that received no treatment (37 days) or AAV9.trastuzumab
(40 days, p=0.862). Transgene expression in brain tissue was similar among mice that
received vector (Fig. S4).
We next sought to determine if NK cells or macrophages played a larger role in
IT AAV9.trastuzumab tumor prophylaxis in the CNS. To do so, we first employed
continuous NK cell depletion by intraperitoneal (IP) administration of the anti-NK1.1
antibody PK136 in our Rag1-/- xenograft tumor model (Fig. 5A-B). Mice that received
AAV9.2.10AmAb with or without NK cell depletion survived a median of 53 and 50 days,
respectively. Mice that received AAV9.trastuzumab tumor prophylaxis and no NK cell
depletion lived a median of 156 days. Median survival of mice that received
AAV9.trastuzumab tumor prophylaxis with continuous NK cell depletion was significantly
shorter, 73 days (p<0.0001, compared to AAV9.trastuzumab without NK cell depletion).
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Formalin-fixed tumors from mice in the NK cell depletion experiment were
subjected to in situ hybridization (ISH) for NK cell-specific Ncr1 (NKp46) RNA. NK cells
infiltrated only tumors from mice given AAV9.trastuzumab without NK cell depletion (Fig.
5C). IgG transgene expression in brain tissue homogenate was comparable between
groups that received vector (Fig. 5D). Ncr1 ISH of spleens was used to confirm
successful depletion of NK cells (Fig. 5E). We also cryosectioned day 20 tumors from
mice given AAV9.trastuzumab, AAV9.2.10AmAb, or no treatment without NK cell
depletion. Immunohistochemical (IHC) staining for Ly-49G2 (Fig. 6) confirms that NK
cells infiltrated day 20 tumors only from mice that received AAV9.trastuzumab tumor
prophylaxis.
To determine if systemically-circulating macrophages play any role in
AAV9.trastuzumab tumor prophylaxis in our model, we employed continuous
macrophage depletion by IP administration of clodronate liposomes. Mice that received
no treatment with or without macrophage depletion survived a median of 53 and 50
days, respectively (Fig. 7A-B). Mice that received AAV9.trastuzumab without
macrophage depletion survived a median of 92 days (p=<0.0001 compared to mice that
received no treatment without macrophage depletion). Mice that received
AAV9.trastuzumab with macrophage depletion survived a median of 70.5 days
(p=0.3268, compared to AAV9.trastuzumab without macrophage depletion). IgG
transgene expression in brain tissue was comparable among groups that received vector
(Fig. 7C), and macrophage depletion was confirmed by IHC staining of spleens for CD68
(Fig. 7D).
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Discussion and further directions
Metastasis of HER2+ breast cancer to the brain is a devastating diagnosis with a
poor prognosis due to a lack of targeted and effective treatments. Although IT
administration of trastuzumab has been reported to slow disease progression and
prolong survival, the benefit is modest, likely due to the rapid turnover of CSF resulting in
poor tumor exposure to antibody. An unmet need for effective treatments exists for
patients with this disease.
The advent of AAV vectors for gene transfer has revolutionized the field of gene
therapy. The discovery of CNS-tropic vectors, such as AAV9, represents a boon for
clinicians seeking to localize biological treatments behind the blood-brain barrier. A
single IT administration of AAV9 vector into the CSF by way of the lateral ventricles or
cisterna magna leads to widespread transduction of neurons and astrocytes throughout
the cortex, cerebellum, and spinal cord, resulting in long-lived production of transgene
product in the CNS compartment [14, 49, 56].
We have successfully demonstrated that AAV9.trastuzumab administered IT at a
moderate vector dose, both as tumor prophylaxis and as tumor treatment, significantly
extends median survival in a xenograft mouse model where the human HER2+ cancer
cell line BT747-M1.ffluc is implanted into the brains of Rag1-/- mice. In the prophylactic
setting, median survival is 2.48 times greater for mice that received AAV9.trastuzumab
tumor prophylaxis than mice that received control AAV vector treatment or no treatment.
Additionally, tumors in mice given AAV9.trastuzumab are smaller at day 47 than tumors
from untreated or AAV9.2.10AmAb-treated mice. In the treatment setting, the median
survival benefit is significant but less, perhaps in part due to the shorter total duration of
exposure of tumor cells to expressed trastuzumab. Additionally, we report that a dose of
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1e11 GC AAV9.trastuzumab administered ICV yields a similar amount of trastuzumab in
brain tissue as does an ICV dose of Herceptin® equivalent to 50 mg in humans when
measured 24 hours after antibody administration.
Our studies also indicate that trastuzumab secreted by neurons and astrocytes
maintains its antigen specificity and effector function despite the fact that these cells do
not normally produce IgG. Using immunofluorescence microscopy, we showed that
HER2+ tumors from mice treated with AAV9.trastuzumab, but not AAV9.2.10AmAb, are
decorated with expressed IgG.
The effector functions of trastuzumab have been widely studied [120, 240].
Trastuzumab bound to HER2 on tumor cells (i) mediates ADCC when its Fc binds to
activating Fcγ receptors (e.g. FcγRIIIa) on immune cells such as NK cells and
macrophages; (ii) prevents initiation of signal transduction when HER2 homodimerizes
or heterodimerizes with other members of the HER family, thus slowing tumor growth;
(iii) blocks proteolytic cleavage of the HER2 ectodomain preventing the remaining
membrane-bound p96 protein from activating pro-growth signaling pathways; (iv)
disrupts pro-angiogenic pathways; and (v) disrupts DNA repair pathways.
The predominant mechanism by which trastuzumab acts against peripheral
HER2+ tumors in patients is ADCC by immune cells carrying activating Fcγ receptors,
such as NK cells and macrophages. We hypothesized that the same would be the case
in our xenograft model. It is important to note that the mouse FcγRs do indeed bind to
human IgG1. Overdijk et al. demonstrate that mouse FcγRs bind to human IgG1 and
activate ADCC, and Bruhns reports that all human IgG subclasses are bound efficiently
by mouse FcgRs and FcRn [241, 242].
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AAV9.trastuzumab tumor prophylaxis fails when administered to NSG mice,
which lack NK cells and functional macrophages compared to Rag1-/- mice, suggesting
an NK cell- or macrophage-mediated mechanism of tumor prophylaxis. When we
depleted NK cells in the Rag1-/- model, the median survival of mice decreased
substantially, indicating that NK cell-driven ADCC of tumor cells is responsible for a
majority of the survival benefit. Additionally, immunofluorescence and
immunohistochemical staining of NK cells in tumors indicates that NK cells infiltrated
only into tumors of mice that received AAV9.trastuzumab tumor prophylaxis, not
untreated or control-treated mice. These NK cells are present in tumors as early as 20
days after tumor implantation and as late as the time of necropsy. To our knowledge,
this is the first time that the predominant mechanism by which trastuzumab works
against HER2+ tumors in the CNS has been reported.
Our macrophage depletion studies indicate that these cells do not contribute
significantly to the anti-tumor effect of AAV9.trastuzumab tumor prophylaxis in this
model. However, as clodronate liposomes do not cross the blood-brain barrier, these
experiments can only address whether systemically-circulating macrophages play a role
in AAV9.trastuzumab tumor prophylaxis. Tissue resident macrophages/microglia may
still contribute in small part to the anti-tumor effect of AAV9.trastuzumab in this model.
Limitations of our studies include our use of a single vector dose, although
studies to determine a minimally effective dose (MED) are in progress. Our mice bore
one brain tumor, but patients often develop multiple metastases. Testing
AAV9.trastuzumab tumor prophylaxis in a model where tumor cells are administered via
carotid artery injection or where brain metastases arise after implantation of a peripheral
tumor would indicate whether our treatment is effective against multiple brain tumors.
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We also employed AAV9.trastuzumab in these studies as a monotherapy.
Unsurprisingly, all mice eventually succumb to outgrowth of tumors, which remain
HER2+ at necropsy. Combining AAV.trastuzumab with chemotherapy and/or
radiotherapy will likely be synergistic against HER2+ BCBM, both in this xenograft model
and in patients.
Trastuzumab infusion is standard of care for patients with HER2-overexpressing
breast cancer, and IT delivery of trastuzumab has been shown to be beneficial.
However, trastuzumab expression cannot be turned off after AAV9-mediated gene
transfer. Related to this, cardiotoxicity is a known side-effect that occurs in a small
subset of patients who receive systemic trastuzumab treatment. Risk factors for
cardiotoxicity have been identified, including previous anthracycline-containing
chemotherapeutic regimens, age, and existing cardiac dysfunction [243-245].
With IT administration of IT AAV9.trastuzumab, we anticipate a lower
concentration of trastuzumab in blood than after IV administration of Herceptin®, which
would be less likely to lead to cardiotoxicity. Regardless, women with CNS metastasis
from HER2+ breast cancer almost always have systemic disease necessitating
treatment with systemic administration of trastuzumab where safety monitoring of
cardiac function is standard. This aspect will be incorporated into the design of our first
in human phase I safety trial.
We plan to first assess the safety, efficacy, and pharmacokinetics of
AAV9.trastuzumab in women with documented CNS lesions from HER2+ breast cancer.
Subject to safety and efficacy in this setting, AAV9.trastuzumab will be subsequently
assessed in a similar patient population with systemically metastatic HER2+ disease
prior to clinical or radiological diagnosis of CNS lesions. Given that AAV transgene
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expression has been documented to persist for years in non-human primates and
humans [246, 247], this approach has the potential to be an integral part of the adjuvant
therapy for patients with early diagnosis of HER2+ breast cancer after curative resection
of the breast lesion.
Given this fact and the results of our experiments, we intend to move
AAV9.trastuzumab toward the clinic. Going forward, our AAV platform has the potential
to be expanded to express other therapeutic antibodies behind the blood brain barrier to
treat CNS diseases and address other unmet needs.

Materials and Methods
Experimental design
IT-administered trastuzumab can increase survival and delay tumor progression
in patients with HER2+ BCBM. However, trastuzumab has been reported to have a halflife in CSF of 12 hours [220]. We aim to administer AAV9.trastuzumab IT such that
trastuzumab can be constitutively secreted by neurons and astrocytes in situ leading to
better tumor exposure to trastuzumab and thus longer median survival. To test our
hypothesis, we chose Rag1-/- mice due to their lack of endogenous IgG and T cell
“leakiness” that can occur in nude mice often used for HER2+ brain tumor xenografts in
the literature. Both Rag1-/- and NSG mice used in these experiments were obtained
from The Jackson Laboratory (Bar Harbor, ME, USA), housed at the barrier facility of the
Translational Research Laboratories (TRL) Vivarium at the University of Pennsylvania,
and maintained according to NIH guidelines for the care and use of animals in research.
All procedures and protocols were approved by the Institutional Animal Care and Use
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Committee (IACUC) of the University of Pennsylvania. The 2.10A mAb control antibody
is a rhesus anti-simian/human immunodeficiency virus (SHIV) IgG, and the
AAV9.2.10AmAb expression construct has the same regulatory elements as
AAV9.trastuzumab. We administered vector to mice at least 21 days before tumor
implantation in the prophylaxis studies and 3 days after tumor implantation in the
treatment studies, because at least 10-14 days are required for vector expression to
reach steady state. Sample size was determined to be a minimum of 8 mice per
experimental group to allow for robust statistical analysis if mice were euthanized due to
complications during or post-tumor implantation. The large prophylaxis study began with
20 mice per group, the treatment study with 8 mice per group, and the NSG and NK cell
depletion studies with 12 mice per group. Macrophage depletion studies began with 9
mice per group, with an additional 2 mice added to AAV9.trastuzumab-treated arms due
to clodronate-related toxicity. Mice found dead rather than euthanized were included
only in the survival analyses and not in downstream transgene expression, histological,
or biodistribution analysis. Studies were conducted without blinding.

Statistics
Survival study p values were calculated using the Log-Rank (Mantel-Cox) test in
GraphPad Prism for Windows version 7 (GraphPad Software). Hazard ratios were
calculated with a Cox regression model using the sts package in Stata (StataCorp).
Tumor diameter comparisons were carried out using Wilcoxon rank-sum test within the
R program (version 3.3.1; https//cran.r-project.org) using the function “wilcox.test.”
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Vector construction
Sequences matching the WHO published amino acid sequences of the heavy
and light chains of trastuzumab were back-translated, codon-optimized, and synthesized
by GeneArt (Life Technologies). Heavy and light chain sequences were preceded by a
human IL-2 secretion signal. The heavy and light chain sequences were cloned into an
AAV expression construct containing an upstream hybrid CMV immediate early
enhancer/chicken beta-actin promoter and a Promega chimeric intron and a downstream
SV40 polyadenylation signal. The heavy and light chain sequences were separated from
each other by an F2A self-cleaving peptide to ensure 1:1 production of heavy and light
chain protein. The construct was flanked by AAV2 inverted terminal repeats. The
resulting pAAV.CMV.PI.trastuzumab.SV40 expression construct was packaged in an
AAV9 capsid by triple transfection of 293 cells and purified as previously described [24].
Vector was titrated using standard qPCR. AAV9.CMV.PI.2.10AmAb.SV40 was obtained
from the Penn Vector Core.

Vector administration
Six to nine-week-old female Rag1-/- (B6.129S7-Rag1tm1Mom/J) mice were
obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and housed at the TRL
Vivarium at the University of Pennsylvania. All animal procedures and protocols were
approved by the IACUC of the University of Pennsylvania. Vector was diluted in sterile
PBS. For IT administration by ICV injection, vector was diluted to 1 x 1011 GC per 5 µL.
For tumor prophylaxis, mice were injected ICV with 1 x 1011 GC of
AAV9.CMV.PI.trastuzumab.SV40 or AAV9.CMV.PI.2.10AmAb.SV40 at least 21 days
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prior to BT474-M1.ffluc tumor implantation. For tumor treatment, mice received BT474M1.ffluc tumors first, and vector was administered by ICV injection 3 days after tumor
implantation.

Orthotopic xenograft model of HER2+ breast cancer brain tumors in Rag1-/- and NSG
mice
The xenograft model was based on previous HER2+ BCBM models reported in
the literature [248-252]. The HER2+ BT474.M1 human ductal carcinoma cell line,
transduced with the lentiviral vector VSVG.HIV.SIN.cPPT.CMV.ffluciferase.WPRE (Penn
Vector Core), was cryopreserved in liquid nitrogen. One week before tumor implantation,
BT474-M1.ffluc cells at passage 56 were thawed, expanded in DMEM/F12 (Corning)
with 10% FBS and 1% penicillin/streptomycin at 37°C and 5% CO2, and passaged three
days before tumor cell implantation. On the day of tumor injection, cells were counted
with a Countess II cytometer (Life Technologies), and suspended at 1x105 cells per 5 µL
in 50%/50% (v/v) PBS/MatriGel® (Corning).
For the injection procedure, mice were anesthetized with ketamine/xylazine. Fur
on the scalp and neck was sheared. A time-release 17-β estradiol pellet (1.7 mg, 90-day
release, Innovative Research of America) was implanted subcutaneously in the dorsum
of the neck and re-administered every 90 days during the study. Mice were fixed in a
stereotaxic apparatus. Exposed skin was cleansed with povidone iodine and 70%
ethanol. A 1 cm anterior-posterior incision was made over the top of the skull. Bregma
was identified. A pneumatic drill was positioned at bregma then moved 0.8 mm posterior
and 2.2 mm left of bregma where a burr hole was drilled in the skull.
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A 25 µL Hamilton syringe was loaded with 5 µL of cell suspension and positioned
in a mechanical injector on the stereotaxic frame. After bringing the needle to 0.8 mm
posterior and 2.2 mm left of bregma, the needle was moved 4.0 mm deep into brain
parenchyma then lifted 1.0 mm to create a pocket into which to inject cells. The needle
was left in place for 5 minutes. The cell suspension was mechanically injected over 10
minutes, and the needle was left in place another 5 minutes before being removed
slowly. After suturing incisions, mice recovered on a 37°C heating pad and were given
100 µL of 2 mg/kg enrofloxacin in PBS and 0.3 mg/kg buprenorphine in PBS
subcutaneously.
Firefly luciferase imaging of tumor growth was not conducted in these studies.
Our previous attempts to do so resulted in many mice developing acute urinary and
kidney complications including hydronephrosis, kidney and bladder stones, and gross
hematuria in the days immediately following the imaging procedure, necessitating
euthanasia of affected mice. 17β estradiol, released from the subcutaneous pellet, has
been reported in the literature to cause renal and urinary pathology[253-255]. It is
possible that some aspect of our model exacerbated underlying kidney or urinary
pathology associated chronic exposure to 17 estradiol.
Mice were monitored daily. When moribund, mice were euthanized by
overexposure to CO2 followed by cervical dislocation. At necropsy, brains and tumor
were either snap-frozen on dry ice and stored at -80°C for transgene expression and
genome copy analysis, cryopreserved in OTC medium using liquid nitrogen, or
preserved in formalin.
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Tumor diameter
Measurement of day 47 tumor diameter was performed with digital Vernier
calipers (Thermo-Fisher). Brains were harvested at necropsy and cut coronally through
the visible tumor injection needle track. The diameter of the tumor in the anterior section
was calculated as the geometric mean of two perpendicular diameter measurements.

NK cell depletion
PK136 (anti-mouse NK1.1) antibody was purified from PK136 hybridoma
supernatant (ATCC® HB-191™) using the protein A purification kit (Sigma) and
supplemented as needed with PK136 available commercially (Leinco Technologies).
Mice were given 100 µg PK136 or PBS intraperitoneally on days 5 and 1 before tumor
implantation, then weekly for the duration of the experiment.

Systemic macrophage depletion
Chlodronate liposomes or PBS liposomes (Nico van Rooijen, Vrije University
Medical Center, Amsterdam, the Netherlands) were injected intraperitoneally at 10 µL
per g body weight on days 5 and 1 before tumor implantation, then weekly for the
duration of the experiment.
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Preparation of serum
Blood was collected by retro-orbital or sub-mandibular bleed into Z-Gel microtube
serum separators (Sarstedt) and incubated at room temperature for 20 minutes. After
centrifuging for 5 minutes at 5000 RPM in a tabletop microcentrifuge (accuSpin micro
17, Thermo-Fisher), serum was stored at -80°C.

Preparation of brain homogenate
Brain homogenates were prepared by chipping frozen brain into tissue lysis
buffer (25 mM Tris-HCl, 5 mM EDTA, 1% Triton-X, 150 mM NaCl, pH 7.6) containing 3
times the normal concentration of cOmplete™ Protease Inhibitor Cocktail Tablets
(Roche). Samples were homogenized with stainless-steal beads on a TissueLyzer II
(Qiagen) at 30 Hz for 2 minutes, frozen at -80°C, thawed, then centrifuged at 17K x g for
60 minutes at 4°C to remove myelin debris. BCA assay (Thermo-Fisher) was used to
determine protein concentration of brain homogenates.

Protein A ELISA
Protein A ELISA was used to quantify trastuzumab and 2.10A mAb expression in
serum and brain homogenates. All steps were performed at room temperature unless
otherwise stated. Plates were washed with a BioTek 405TS microplate washer with
PBS + 0.05% Tween-20. Protein A (Sigma) was suspended in PBS and stored at -20°C.
Costar® 96-well EasyWash™ ELISA assay plates (Corning) were coated with 5 µg/mL
protein A in PBS overnight at 4°C then blocked with PBS + 0.5% bovine serum albumin
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(Sigma). Samples were diluted in PBS and plated. Herceptin® (Roche) was used as a
quantitative standard. For brain homogenate ELISAs, brain homogenate from
untransduced mice was spiked into the standard curve wells at a dilution equal to that of
samples on the plate. After washing, plates were incubated with AffiniPure polyclonal
goat anti-human IgG-biotin (Jackson ImmunoResearch Labs) followed by streptavidinhorseradish peroxidase (Abcam). Plates were developed with TMB substrate, stopped
with 2N H2SO4, then read using a SpectraMax M3 (Molecular Devices) plate reader at
450 nm.

Biodistribution by qPCR
AAV9 vector genome copies in brain were quantified using TaqMan qPCR
(Thermo-Fisher). Briefly, frozen brain tissue was chipped into ALT Buffer (Qiagen) and
homogenized with steel beads using a TissueLyzerII. Phenol:chloroform:isoamyl alcohol
(25:24:1, Sigma) extraction and isopropanol precipitation was used to isolate tissue
DNA. For TaqMan qPCR, primers and probe were designed against the SV40
polyadenylation signal of the vector.

Histology
HER2 staining was performed on formalin-fixed paraffin-embedded tissue
samples. Sections were deparaffinized through a xylene and ethanol series, boiled in a
microwave for 6 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval, treated
sequentially with 2% H2O2 (15 min; Sigma), avidin/biotin blocking reagents (15 min each;
Vector Laboratories), and blocking buffer (1% donkey serum in PBS + 0.2% Triton for 10
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min) followed by incubation with primary antibody (1 h, rabbit anti-HER2, Abcam
ab2428) and biotinylated secondary antibody (45 min; biotinylated donkey anti-rabbit,
Jackson Immunoresearch, West Grove, PA) diluted in blocking buffer. Bound antibodies
were visualized with a Vectastain Elite ABC kit (Vector Laboratories) using DAB as
substrate. Sections were counterstained with hematoxylin to show nuclei.
Immunofluorescence staining for human IgG was performed on cryosections.
Sections were fixed in 4% paraformaldehyde in PBS for 10 minutes, permeabilized and
blocked in 0.2% Triton in PBS containing 1% donkey serum for 30 minutes, and
incubated for 1 hour with a goat antibody against the crystalizable fragment (Fc) of
human IgG (Jackson Immunoresearch Laboratories, West Grove, PA; 109-005-098)
diluted in 1% donkey serum/PBS. After washing sections in PBS, bound primary
antibodies were detected with FITC-labeled secondary donkey anti-goat antibodies
(Jackson Immunoresearch Laboratories) diluted in 1% donkey serum/PBS. After
washing in PBS, sections were mounted with Vectashield containing DAPI as nuclear
counterstain.
Immunohistochemistry to detect NK cells and HER2 was also performed on
cryosections. Sections for NK cell staining were fixed in acetone at -20ºC for 7 minutes,
air dried, sequentially treated with 0.3% H2O2 in PBS for 10 minutes, avidin/biotin
blocking reagents (15 minutes each; Vector Laboratories), and blocking buffer (1%
donkey serum in PBS, 20 minutes). Sections for HER2 staining were fixed in 4%
paraformaldehyde in PBS for 10 minutes, then permeabilized in 0.2% Triton in PBS (30
minutes) and sequentially treated with 0.3% H2O2 in PBS (10 minutes) and avidin/biotin
blocking reagents (15 minutes each; Vector Laboratories). Sections were then blocked
with 1% donkey serum in PBS for 20 minutes, then treated with primary (1 hour) and
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corresponding biotinylated secondary antibodies (45 minutes; Jackson Immunoresearch)
diluted in 1% donkey serum in PBS. Primary antibodies were as follows: rat anti-mouse
Ly-49G2 (clone 4D11, BD Pharmingen) for NK cells or rabbit anti-mouse Erb2 (Abcam
ab2428) for HER2. A Vectastain Elite ABC kit was used according to the manufacturer's
instructions with DAB as substrate.
To detect NK cells on formalin-fixed paraffin-embedded sections, in situ
hybridization was performed using the ViewRNA ISH Tissue Assay Kit (Thermo Fisher)
according to the manufacturer’s protocol. Z-shaped probe pairs specific for mouse Ncr1
(natural cytotoxicity triggering receptor 1, NKp46) RNA were synthesized by the kit
manufacturer. The deposition of Fast Red precipitates indicating positive signals was
imaged by fluorescence microscopy using a rhodamine filter set. Sections were
counterstained with DAPI to show nuclei.

ICV Herceptin® and AAV9.trastuzumab administration for quantification of trastuzumab
in brain tissue
AAV9.trastuzumab was diluted in PBS. 1e11 GC per Rag1-/- mouse was
delivered ICV in a final volume of 10 µL. Two weeks later, brains were harvested.
Herceptin® was diluted in PBS and administered ICV in a 10 µL volume at a
dose of 15 µg/mouse brain, which is roughly equivalent to a 50 mg IT dose in humans by
brain mass. Brains were harvested 24, 48, and 168 hours after ICV administration of
Herceptin®. Brains were homogenized as described above in 1 mL tissue lysis buffer.
Protein A ELISA, performed as described above, was used to determine ng/mL of
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trastuzumab in brain homogenate. Multiplying this trastuzumab concentration by the
homogenate volume of 1 mL yielded approximate ng trastuzumab per brain.

Study Approval and Animal Welfare
All procedures and protocols were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Pennsylvania.
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Tables & Table Legends

Reference

Dose
LM or
(total cumulative
Intraparenchymal
dose)

Preusser et al.

LC

Hofer et al.

LC

Mego et al.

LC

Mego et al.

LC

Oliviera et al.

LC

5-100mg
(250 mg)
100-150mg
(1110 mg)
20-40mg (180
mg)
20-100mg
(440 mg)
25 mg
(825 mg)

Ferrario et al.

LC

20-40 mg
(610 mg)

Colozza et al.

Intraparenchymal

12.5 mg
(287.5 mg)

Allison et al.

LC

20-60 mg

Allison et al.

LC

20-60 mg

Allison et al.

LC

20-60 mg

Allison et al.

LC

20-60 mg

Stemmler et al.
2008

LC

Mir et al.

LC

Shojima et al.

LC

Platini et al.

LC

Stemmler et al.
2006
Laufman and
Forstoefel

20 mg
(80mg)
20-100 mg
(460mg)
25 mg/kg
(>150 mg/kg)
20-25 mg
(405-495 mg)

Frequency

Concurrent treatments
(if indicated)

MRI or Clinical
Response

Duration
of
response
(months)

AEs/SAEs

Twice weekly

IV PLD, IV trastuzumab

MRI progression

NR

None

Every 2-3
weeks

IV trastuzumab

CR

>5.4

None

PR

13.5
months

Postradiation
leukoencephalopathy,
ischemic lesion in frontotemporal region of left brain

PR

7.5 months

None

SD

9

None

PR

10

G3: anemia, neutropenia

>23

SD

19

None

>37

>1

None

>1

>3.5

None

>3.5

Weekly

Weekly
Weekly
Weekly
Every 3
weeks
Every 1-2
weeks
Every 1-2
weeks
Every 1-2
weeks
Every 1-2
weeks
Twice weekly

LC

40-105 mg
(1090 mg)

Not
reported
Not
reported

None
None

1.3

None

Not
reported
Not
reported
1.3

2

None

7

PR

>1.5

None

>1.5

Every week

5-20 mg (35 mg) Over 2 weeks

Kordbacheh et
al.

IT MTX

Clinical
improvement
Clinical
improvement
SD -->
progression
SD -->
progression
Clinical
improvement

7.5
months
18.4
months

SD

LC

25 mg

IV trastuzumab

13.5

Every week

4-20 mg (70 mg) Twice weekly

LC

IT MTX, IT cytarabine, IT
hydrocortisone
IT prednisone, IT capecitabine,
IV trastuzumab
IT MTX, IT cytarabine, IT
hydrocortisone, IV
trastuzumab, IV PLV

1.5
months
5.4
months

Every week

LC

Brandt et al.

IT MTX, IT cytarabine, IT
hydrocortisone

OS
(months)

Every other
day for 3
weeks, then
weekly
Every 1-2
weeks

IV paclitaxel, IV trastuzumab

MRI progression

5

None

>21

IV trastuzumab, PO
capecitabine
IT MTX, IT Thiotepa, IV
paclitaxel, IV trastuzumab

Clinical
improvement

5.2

None

>5.2

SD

1.5

None

2.2

IV trastuzumab, IV
capecitabine, IV lapatinib

Clinical
improvement

>46
months

None

>46
months

IT MTX

CR

>7.4

None

7.4

Lapatinib, IV trastuzumab
emtansine

SD

46

Meningitis (Ommaya
replaced)

46

SD

>6

None

>6

5-80 mg

Twice weekly
for one month
then every
two weeks

Bousquet et al. Intraparenchymal

25-100 mg

Every 3
weeks, then
weekly, then
every three
days

Dumitrescu et
al.

LC

20-100 mg

Weekly

IV trastuzumab

PR

2

None

2

Park et al.

LC

25-50 mg

Weekly

IT methotrexate

PR

18

None

20

Lu et al.

LC

Park et al.

LC

25-50 mg

Weekly

IV trastuzumab, IV paclitaxel

PR

13

None

>13

Pluchart et al.

LC

21mg

Weekly

IV trastuzumab, lapatinib

PR

14

None

>14

Gulia et al.

LC

50-150mg

Twice weekly,
weekly, every
3 weeks

lapatinib, letrozole, IT
hydrocortisone

PR

4

None

Not
reported

Giulia et al.

LC

150mg

Every 3
weeks,
weekly, every
3 days

IV trastuzumab, lapatinib, IT
hydrocortisone

SD

7

None

>7

Table 1. A summary of case reports of IT trastuzumab used to treat HER2+ BCBM. [219221, 256-276]. Table adapted from [219, 257-259]. (MTX, methotrexate; OS, overall survival; CR,
complete response; PR, partial response; SD, stable disease; AE, adverse event; SAE, serious
adverse event; LC, leptomeningeal carcinomatosis; PO, by mouth)
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IT Trastuzumab Clinical Trials

Intrathecal Trastuzumab for
Leptomeningeal Metastases in
HER2+ Breast Cancer (Phase I)

PI

Raizer et al.
(Northwestern)

Size

13 women with HER2
positive BC, 1 man with
glioblastoma, and one
woman with anaplastic
ependymoma

Dose

Safety

Phase II study?

Expected
completion
dates

Clinical benefit so far?

3 patients at
10mg, 3 at
20mg, 1 at
40mg, 1 at
60mg, and 7 at
80

AEs/SAEs = 1 patient
had grade 4 doselimiting toxicity
(arachnoiditis); one
patient had ommaya
removed due to
infection

Expected primary
Phase I/II study
endpoint results
at 40 mg max
3/2018, estimated N/A
dose in
study completion
progress
date 3/2019

No >3 tox or neuro
toxicity; maximum
tolerated dose not
reached; treatment
well-tolerated in
general

Expected primary
Phase II at 150 endpoint results 9/
mg dose in
2017, estimated
progress
study completion
date 5/2018

Safety and Efficacy of Intrathecal
Trastuzumab Administration in
Metastatic HER2 Positive Breast Gutierrez et al.
Cancer Patients Developing
(Institut Curie)
Carcinomatous Meningitis (Phase
I/II Study)

19 patients

30-150mg
(aimed for 30
ug/mL in CSF)

Intrathecal Pertuzumab and
Trastuzumab in Patients with New
Untreated Asymptomatic or Low Blackwell et al.
Symptomatic Brain Metastasis in (Duke)
HER2 Positive Breast Cancer
(Phase I/II)

36 patients

80 mg
trastuzumab, 10N/A
80 mg
pertuzumab

N/A

*5 patients out of 19
had evident clinical
benefit *All had 8 or
more administrations of
IT Herceptin® (mean
23)
*Effective
dose(s) not mentioned

Expected primary
endpoint results
N/A
2/2019, study
complete 8/2019

Table 2. A summary of ongoing clinical trials using IT Herceptin® to treat HER2+ BCBM.
(clinicaltrials.gov)
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Fig. 1. IT AAV9.trastuzumab tumor prophylaxis. (A) Kaplan-Meyer survival curves for mice
that received IT AAV9.trastuzumab tumor prophylaxis, IT AAV9.2.10AmAb control treatment, or
no treatment at least 21 days before tumor challenge. (B) Tabulated survival and statistical data
for Fig. 1A. (C-D) Serum expression of trastuzumab and 2.10A mAb measured by protein A
ELISA. (E) IgG transgene expression in brain tissue measured by protein A ELISA of brain
homogenate and graphed as a percent of total protein in brain homogenate. (F) Positive HER2
immunohistochemistry (IHC) staining of BT474.M1.ffluc tumors from the necropsies of mice from
Fig. 1A.
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Fig. 2. IT AAV9.trastuzumab tumor treatment. (A) Kaplan-Meyer survival curves for mice that
received IT AAV9.trastuzumab tumor treatment, IT AAV9.2.10AmAb control treatment, or no
treatment 3 days after tumor challenge. (B) Tabulated survival and statistical data for Fig. 2A.
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Fig. 3. Day 47 tumor diameter and IgG immunofluorescence microscopy. (A) IT
AAV9.trastuzumab tumor prophylaxis yielded tumors of significantly smaller diameter than IT
AAV9.2.10AmAb control treatment or no treatment when measured 47 days after tumor cell
implantation (p=0.0159). (B) IgG transgene expression in brain tissue measured by protein A
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ELISA. (D) Immunofluorescence staining for human/rhesus IgG in day 47 tumor cryosections.
Representative HER2 IHC staining is shown in Fig. S5
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Fig. 4. IT AAV9.trastuzumab tumor prophylaxis in NOD scid gamma mice. (A) Kaplan-Meyer
survival curves for mice that received IT AAV9.trastuzumab tumor treatment or no treatment at
least 21 days before tumor challenge. (B) Tabulated survival and statistical data for Fig. 4A.
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Fig. 5. IT AAV9.trastuzumab tumor prophylaxis in the setting of continuous NK cell
depletion. (A) Kaplan-Meyer survival curves for mice that received IT AAV9.trastuzumab tumor
prophylaxis or IT AAV9.2.10AmAb control treatment with or without continuous NK cell depletion
using PK136 (anti-NK1.1 antibody). (B) Tabulated survival and statistical data for Fig. 5A. (C) In
situ hybridization for Ncr1 (NKp46) RNA (red) in formalin-fixed paraffin-embedded tumors
harvested at necropsy from the experiment in Fig. 5A. DAPI (blue). (D) IgG transgene expression
in brain tissue measured by protein A ELISA of brain homogenate and graphed as a percent of
total protein in brain homogenate. (E) In situ hybridization of Ncr1 RNA in formalin-fixed paraffinembedded spleens harvested at necropsy.
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Fig. 6. NK cell immunohistochemical staining of day 20 tumors. Immunohistochemical
staining for NK cells (Ly-49G2) performed on day 20 tumor cryosections.
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Fig. 7. IT AAV9.trastuzumab tumor prophylaxis in the setting of continuous systemic
macrophage depletion. (A) Kaplan-Meyer survival curves for mice that received IT
AAV9.trastuzumab tumor prophylaxis or IT AAV9.2.10AmAb control treatment with or without
systemic macrophage depletion. (B) Tabulated survival and statistical data for Fig. 6A. (C) IgG
transgene expression in brain tissue measured by protein A ELISA of brain homogenate and
graphed as a percent of total protein in brain homogenate. (D) CD68 IHC staining of formalinfixed paraffin-embedded spleens harvested at necropsy from animals treated with liposomal PBS
or liposomal clodronate.

88

Supplementary Materials:

G e n o m e c o p ie s in b r a in

G e n o m e c o p ie s

p e r µg b r a in D N A

10 7
10 6
10 5
10 4
10 3
10 2

A

A

V

9

.t

ra

s

tu

zu

m

a

b

A

A

V

9

.2

.1

0

A

m

A

b

Fig S1. Biodistribution of vector genome copies in brain. AAV9 genome copies in brain
tissue from experiment in Fig. 1 determined by qPCR.
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Fig S2. Trastuzumab quantified in brain tissue. 1e11 GC AAV9.trastuzumab or 15 µg
Herceptin® in PBS was administered ICV to mice. Brains were harvested after the duration of
time indicated for trastuzumab quantification in tissue.
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Fig S3. Anti-IgG immunofluorescence of day 20 and day 47 tumor cryosections. (A) Green
channel (human/rhesus IgG) overexposures of day 47 tumors (Fig. 3D) from mice that
received IT AAV9.trastuzumab prophylaxis. (B) anti-IgG immunofluorescence staining of
day 20 tumor cryosections.
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staining of day 47 BT474.M1.ffluc tumors from the necropsies of mice in the experiment
in Fig. 3D.
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